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COGNITIVE DYSFUNCTION IN CANCER: NEUROIMAGING AND GENETIC 
APPROACHES TO IDENTIFY BIOLOGICAL MECHANISMS 
 
Although cancer and treatment-associated cognitive dysfunction has been 
well-documented in the literature, much work remains to elucidate the biological 
mechanisms driving this effect, hampering current therapeutic efforts. To address 
this gap, we first reviewed studies utilizing neuroimaging to characterize cognitive 
dysfunction in cancer, as studies of neurodegenerative diseases point to 
neuroimaging as a sensitive measure of cognitive dysfunction. This review 
highlighted the need for longitudinal imaging studies of cancer and treatment-
related changes in cerebral structure and function. Subsequently, we utilized 
multimodal neuroimaging techniques in a female breast cancer cohort to 
investigate the longitudinal impact of cancer and chemotherapy treatment on 
cerebral perfusion and gray matter. Our findings indicate that chemotherapy is 
associated with elevated perfusion, primarily in posterior brain regions, as well as 
depressed frontal perfusion associated with decreased frontal gray matter 
density. This pattern of results suggests the involvement of multiple mechanisms 
of chemotherapy-induced cognitive dysfunction. We also investigated the 
relationship of cognitive dysfunction and chemotherapy-induced peripheral 
neuropathy (CIPN), another type of chemotherapy-related nervous system 
sequelae, again utilizing multimodal, longitudinal neuroimaging, and found that 
peripheral neuropathy symptoms following chemotherapy were associated with 
changes in cerebral perfusion and gray matter density. Together, these findings 
support the hypothesis that multiple biological mechanisms drive cancer and 
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treatment-related cognitive dysfunction. Interestingly, although cancer is 
associated with cognitive dysfunction, epidemiological studies have shown that 
cancer and Alzheimer’s disease (AD) are inversely correlated. To extend our 
imaging analysis beyond breast cancer, we leveraged the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) cohort to investigate the inverse relationship of 
cancer and AD and investigate the impact of both of these diseases on gray 
matter density. We found that though the inverse relationship of these diseases 
was replicated in the ADNI cohort, cancer history was associated with lower gray 
matter density, similar to findings from breast cancer studies, independent of AD 
diagnostic group. Finally, we reviewed microRNA studies, as microRNAs are 
important regulators of many cell signaling pathways and have been actively 
investigated in relation to both diseases. This review suggests several pathways 
that may be driving the inverse association and may contribute to cognitive 
dysfunction. 
Andrew J. Saykin, PsyD, Chair 
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I. Introduction 
A. Cancer and Cognitive Dysfunction 
Cognitive dysfunction in breast cancer, also referred to as ‘chemobrain’ in 
common parlance, has become a research focus of increasing concern given the 
high five-year survival rate of approximately 89% for the U.S. population from 
2004 to 2010 [1]. Although there has been some research on cognitive 
dysfunction in other types of cancer, breast cancer has become the apparent 
‘model system’ for cancer and treatment-related cognitive dysfunction given the 
high survival rate, availability of subjects, and subsequent focus on survivor 
quality of life. To date, the majority of this research has been conducted on the 
effects of chemotherapy treatment, although there is also evidence that breast 
cancer may have some impact on cerebral function independent of treatment as 
well [2-5]. Research has indicated that chemotherapy treatment is associated 
with more cognitive complaints, lower neuropsychological test scores, and a 
number of altered neurophysiological measures obtained via neuroimaging, 
which can persist for years following treatment [6-19]. 
Increasingly, studies of cancer and chemotherapy-induced cognitive 
dysfunction are incorporating neuroimaging methodologies. Studies of 
Alzheimer’s disease (AD) have suggested that various neuroimaging 
methodologies may be more sensitive than clinical neuropsychological testing, as 
neuroimaging can detect biological changes years before an individual would 
receive a clinical diagnosis [20]. Neuroimaging studies of cancer and treatment-
related cognitive dysfunction were initially conducted in cancer survivors. These 
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studies showed significant structural and functional changes; however, there 
were a number of limitations to these study designs, including in many instances 
the lack of control groups of cancer survivors not treated with chemotherapy, as 
well as the inability to track change over time to better understand the short and 
long-term consequences of cancer and treatment. To address this gap, more 
recent studies have investigated cognitive function in pre-treatment cancer 
patients, and there have also been a handful of reported longitudinal 
neuroimaging studies measuring pre- to post-treatment cognitive changes. 
Significant findings from these studies, discussed in more detail in Chapter II, 
highlight the utility of these methodologies and the importance of continuing to 
employ new methodological advances in this field. The cerebral structural and 
functional information provided by neuroimaging studies may better elucidate the 
biological mechanisms of cancer and treatment-related cognitive dysfunction, 
and help direct future research and therapeutic efforts.  
B. Posited Mechanisms of Cancer and Treatment-Related Cognitive 
Dysfunction 
There are a number of biological mechanisms which have been proposed to 
contribute to the development and persistence of cancer and treatment-related 
cognitive dysfunction [21-23]. Although direct neurotoxicity was initially dismissed 
given the known interference of the blood brain barrier with chemotherapy 
delivery to the brain, studies have shown higher than expected levels of some 
chemotherapeutic agents in brain tissues, reviving this hypothesis [24-28]. 
Indirect mechanisms leading to cognitive dysfunction have been posited to 
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include activation or perturbation of inflammatory and immune responses, 
oxidative stress, DNA repair, telomere shortening, and angiogenic pathways, as 
well as perturbations in hormone levels and/or signaling by cancer and/or 
associated treatment(s), particularly chemotherapy and hormone therapies 
(Figure 1). Furthermore, some of these pathways have been suggested to feed 
back on themselves; for example, cancer and chemotherapy-related telomere 
shortening may also be exacerbated by cancer and treatment-related increases 
in oxidative stress [21]. It is reasonable to posit that more than one mechanism is 
likely to contribute to cancer and treatment-related cognitive dysfunction, and 
furthermore that these contributions may vary across individuals; however, at the 
time that this work was conceptualized, there were very few studies equipped to 
address this question. Multimodal imaging studies might begin to do so, by 
investigating whether results observed with different types of imaging modalities, 
including gray and white matter changes and cerebral function, are correlated or 
independent.  
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Figure 1. Biological Mechanisms Posited to Drive Cancer and Treatment-
Related Cognitive Dysfunction. Diagram arrows show directionality of 
hypothesized mechanisms from cancer and treatment (initiation, orange box) to 
posited mechanisms (yellow boxes) to cerebral structure and functional 
alterations and cognitive dysfunction (outcomes, blue box). A final arrow from 
cancer and treatment to outcome represents the hypothesis of direct 
neurotoxicity resulting from chemotherapy treatment.  
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We hypothesized that investigation of biological mechanisms driving cancer 
and treatment-related cognitive dysfunction may be more successful if expanded 
to encompass more types of cancer and treatment-related sequelae. Of 
particular interest, although chemotherapy treatment has been shown to cause 
both peripheral and central nervous system sequelae, there is a lack of 
investigation of the possible correlation of these sequelae. Boland and 
colleagues (2014) provided evidence that study participants with multiple 
myeloma experiencing chemotherapy-induced peripheral neuropathy (CIPN) 
demonstrated altered cerebral activation during painful stimulation as measured 
with functional MRI (fMRI) compared to healthy controls, suggesting that these 
patients experienced a different mechanism of central pain processing [29]. More 
evidence is needed to show whether this peripheral nervous system sequela 
relates to cerebral blood flow and structure, or to previously observed 
neuroimaging measures of chemotherapy treatment-related effects. Given that 
genetic factors such as variants affecting chemotherapy drug clearance (and 
toxicity) or DNA repair could theoretically predispose to both sequelae, it is 
possible that there exists a subgroup of patients at greater risk to develop both. 
Determining whether there is a correlation between these sequelae could provide 
direction for future therapeutic efforts. 
Similarly, it has been suggested in previous literature that only a subgroup of 
patients treated with chemotherapy experience significant cognitive effects; 
identification of this more vulnerable subgroup could be a useful factor in 
treatment decision-making [21,22,30,31]. Genetics have been repeatedly posited 
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to impact cognitive sensitivity to treatment; however, to date, there is a paucity of 
research on this topic [18,21,22]. Only two studies on breast cancer survivors 
have found genetic association with neuropsychological performance; both 
tested specific hypotheses involving one candidate gene apiece [32,33]. No 
studies have been performed using results from neuroimaging analyses as 
quantitative traits, though these phenotypes might be more sensitive, given the 
subclinical range of neuropsychological change typically observed in cancer 
survivors, indicating a significant gap in the literature. 
C. Cognitive Dysfunction in Cancer and Alzheimer’s Disease 
Although findings from neuroimaging studies have provided a number of 
useful endophenotypes for genetic analyses, these studies have not yet been 
performed. Genetic analysis is limited by the relatively small number of 
participants typically collected by these studies. To begin to overcome this 
limitation, it was posited that larger neuroimaging datasets of other types of 
cognitive dysfunction might be leveraged. The Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) cohort includes over sixteen hundred participants, 
approximately a third of whom are cancer survivors, with extensive data including 
a number of different types of neuroimaging, neuropsychological testing, self-
reported cognitive function, genotyping, and medical and demographic 
information.  
This cohort provided a unique opportunity to address questions raised by 
earlier studies of cancer and treatment-related cognitive dysfunction. The many 
types of cancer included in the sample permitted analysis to determine whether 
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findings from cognitive dysfunction studies in breast cancer survivors are more 
broadly applicable across other cancer types. If this is so, this cohort may in the 
future provide an opportunity for future research to utilize neuroimaging 
measures of cancer and treatment-related cognitive dysfunction as quantitative 
traits in genome-wide association studies, providing the first genome-wide 
investigation of cancer and treatment-related cognitive dysfunction. More 
immediately, this cohort also presented a chance to investigate the impact of 
cancer and treatment-related cognitive dysfunction on the neurodegenerative 
process of AD. 
The impact of cancer and treatment-related cognitive dysfunction on AD is 
particularly interesting in light of apparently conflicting observations and 
hypotheses. On the one hand, it has been suggested that there are common 
biological mechanisms underlying the development of cancer, related cognitive 
dysfunction, and aging, and that there are some similar cerebral structural and 
function changes observed in neuroimaging studies of cancer compared to those 
of healthy aging and AD [34]. On the other hand, there are a growing number of 
epidemiological studies that indicate that cancer and AD are inversely 
associated, suggesting that cancer history may actually protect individuals from 
developing AD [35-42]. Because most studies of cancer and treatment-related 
cognitive dysfunction to date have been conducted in adults aged less than sixty-
five years, there is currently insufficient evidence to directly address the impact of 
cancer and treatment-related cognitive dysfunction on the aging process and 
neurodegenerative disease. Determining the impact of cancer and treatment on 
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cerebral structure and function in older patients, particularly in a cohort of 
patients spanning the neurodegenerative disease spectrum from cognitively 
normal individuals to those with AD, would aid in clarifying this apparent conflict 
of evidence, as well as potentially elucidating some of the biological mechanisms 
driving these changes. 
Another tactic toward this goal is to synthesize and compare the current 
literature examining the genetic mechanisms driving cancer and AD. An excellent 
example of this is the review by Tabares-Seisdedos and colleagues (2011), 
which highlighted a number of shared genes identified independently in studies 
of cancer and AD [43]. As intriguing as this overlap is, there is still much work to 
be done describing the biological mechanisms driving the inverse association of 
these diseases. We hypothesized that a useful extension of this work might 
similarly compare studies of cancer and AD to identify microRNAs (miRNAs) 
which were involved in both disease processes. Since one miRNA may regulate 
many genes, and be involved in many cell signaling pathways, we posited that 
identifying miRNAs important to both disease processes might shed more light 
on biological mechanisms driving both diseases, and provide more information to 
address the mechanisms driving the inverse association of cancer and AD.  
D. Statement of Purpose 
With the large and increasing number of cancer survivors, it is becoming 
increasingly important to better understand cancer- and treatment-related 
cognitive dysfunction, with the eventual goal of developing more effective 
therapies and interventions. Additionally, considering the growing elderly 
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population, it is important to better comprehend how cancer survivorship and 
potential cognitive dysfunction may impact the aging process and the 
development of AD.  
Accordingly, the goals of this work were as follows: 
1. Critically review existing neuroimaging studies of cancer and treatment-
related cognitive dysfunction, and utilize available longitudinal neuroimaging 
breast cancer cohort data to address gaps in the literature. 
2. Investigate the impact of cancer history on AD age of onset and cerebral 
gray matter density. 
3.  Critically review studies of miRNAs in cancer and AD to elucidate 
biological mechanisms potentially contributing to the inverse association of these 
diseases. 
We hypothesized that applying advanced multimodal neuroimaging 
methodology to the study of cancer and treatment-related nervous system 
sequelae would aid in clarifying the relationship of results observed in previous 
studies, and addressing the question of whether multiple biological mechanisms 
drive cognitive dysfunction. Additionally, we hypothesized that results similar to 
those observed in previous cancer neuroimaging studies would be observed in 
the ADNI cohort, extending these findings beyond breast cancer. Finally, we 
hypothesized that a review of miRNAs identified independently in cancer and AD 
would yield common biological pathways, which might prove key to the inverse 
association of these diseases and provide direction to future therapeutic efforts 
for both diseases.  
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II. Neuroimaging, Cancer, and Cognition: State of the Knowledge 
A. Introduction 
Multiple neuroimaging techniques have been applied in studies of cancer- 
and chemotherapy treatment-related cognitive dysfunction, with promising 
results. Magnetic resonance imaging (MRI) most commonly is employed. MRI 
uses radio frequencies to manipulate magnetization of various types of nuclei in 
the body, with the resulting signatures used to produce detailed 2- or 3-
dimensional images [44,45]. This technology has been adapted to measure a 
number of different factors, including brain gray matter (GM), white matter (WM), 
and neural activity using functional MRI (fMRI). WM structure and directional 
diffusion, or ‘fractional anisotropy’ (FA), is measured through diffusion tensor 
imaging (DTI) of magnetized cerebral water flow [46,47]. Brain activation is 
obtained using magnetized hemoglobin to observe oxygenated blood flow; 
increased blood flow to active areas is measured during tasks, and fMRI has 
been reliably correlated with neural activity [48-50]. Proton MR spectroscopy (1H-
MRS) also uses magnetic resonance technology to measure levels of brain 
metabolites and neurochemical changes [51]. MRI techniques have the 
advantage of being non-invasive and do not require ionizing radiation, permitting 
multiple measurements and longitudinal studies. Positron emission tomography 
(PET) is another technique that has been employed to measure brain activity and 
metabolism using an injected radioactive tracer coupled to a bioactive molecule; 
two common tracers which will be discussed are [O-15], which measures blood 
flow, and [F-18] Fluorodeoxyglucose (FDG), which measures metabolism [52-
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54]. These techniques can be used to investigate neurophysiological changes 
and may help explain the mechanisms of cognitive dysfunction in cancer 
patients. 
The purpose of this research brief is to review the current literature on 
neuroimaging studies of cancer and chemotherapy-induced cerebral alterations, 
and to provide perspective on the state of research and future directions. Our 
primary goal is to review and synthesize the evidence regarding the impact of 
non-central nervous system cancer and related treatment on brain structure and 
function. Treatments administered for cancers in the central nervous system 
(CNS) and lymphatic systems operate under different parameters and goals and 
are beyond the scope of this review [55]. Findings from imaging studies have the 
potential to identify causal mechanisms and possible therapeutic directions for 
cancer and treatment-related cognitive dysfunction. 
B. Overview of Findings 
We reviewed 35 neuroimaging studies. The overwhelming majority of the 
work in this area has been focused on breast cancer patients, with 27 breast 
cancer studies [2,4-17,23,56-67] and only eight studies in other cancers [68-75]. 
In the breast cancer studies, we noted that 18 studies were focused on survivors 
[6-11,13,14,23,56,57,59-63,66,67], three were pre-treatment cancer studies 
[2,4,5], and six were prospective, longitudinal studies in which women were 
followed pre- and post-treatment [12,15-17,58,64]. These studies are grouped by 
methodology and information is provided regarding authors, cohorts, methods, 
and results in Tables 1-3. The majority of non-breast cancer studies (see Table 
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4) were focused on the association of metabolism with psychological factors or 
cancer. In summary, research to date has been focused on the cognitive effects 
of breast cancer treatment, likely due to the large pool of survivors with cognitive 
concerns [18,23,65,76]. This brief provides an overview including all types of 
neuroimaging studies on multiple types of cancer.  
C. Breast Cancer Survivor Studies 
Neuroimaging studies began with a focus on survivors treated with 
chemotherapy. Initial findings on this topic presented in 2003 indicated that 
chemotherapy treatment was associated with structural changes in gray matter 
(GM), white matter (WM) loss, and abnormal regional cerebral metabolism 
measured by PET [23,77,78]. The focus of these breast cancer studies (Table 1) 
was on patients treated with chemotherapy (Ctx+). All studies included a Ctx+ 
category, and 15 included healthy controls (HC) [6-8,11,13,14,23,56,57,59-
63,66]. However, only seven studies included non-chemotherapy-treated 
survivors (Ctx-), so possible interpretations are limited since in most studies 
differentiation between changes caused by chemotherapy treatment versus 
cancer was not possible [9-11,13,61,66,67].   
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Table 1. Breast Cancer Survivor Neuroimaging Studies 
Study Cohort PCIa Method Results 
Saykin et al. [23] 12 Ctx+b, 12 HC >5Y sMRI Ctx+: ↓ WM and GM 
Yoshikawa et al. 
[67] 
44 Ctx+, 31 Ctx- >3Y sMRI, NP Ctx+: No treatment associations 
Ferguson et al. 
[59] 
1 Ctx+, 1 HC 22M 
s/fMRI, NP, 
SR 
Ctx+: ↑ SR, WM damage, WMem 
activation 
Silverman et al. 
[66] 
16 Ctx+, 5 Ctx-, 
13 HC 
5-10Y 
O-15 & 
FDG PET, 
NP 
Ctx+: altered CBF during memory 
task; resting metabolism correlated 
with task performance 
Inagaki et al. [61] 
1Y: 51 Ctx+, 54 
Ctx-, 55 HC; 3Y: 
73 Ctx+, 59 Ctx-, 
37 HC 
1Y 
and 
3Y 
sMRI, NP 
1Y Ctx+: ↓ GM and WM vs. Ctx-, not 
vs. H.  
3Y Ctx+: no treatment association with 
GM/WM 
Abraham et al. 
[56] 
10 Ctx+, 9 HC 22M DTI, NP Ctx+: ↓ PS, FA 
Kesler et al. [62] 14 Ctx+, 14 HC >6M fMRI 
Ctx+: activation ↓ encoding, ↑ recall in 
VDM task 
Kesler et al. [13] 
25 Ctx+, 19 Ctx-, 
18 HC 
5Y 
fMRI, NP, 
SR 
Ctx+ & Ctx-: ↓ activation for EF task 
Ctx+: ↑ SR complaints, NP errors, ↓ 
PS, ↓ activation correlated with SR, 
disease severity 
de Ruiter et al. 
[10] 
19 Ctx+, 15 Ctx- >9Y fMRI, NP 
HD Ctx+: ↓ activation for EF and 
EMem tasks, NP 
Deprez et al. [11] 
17 Ctx+, 10 Ctx-, 
18 HC 
2-4M 
DTI, NP, 
SR 
Ctx+: ↓ FA, ↑ MD vs. Ctx- and HC; FA 
correlated with attention, PS, SR 
Bergouignan et al. 
[6] 
16 Ctx+, 21 HC 
18-
36M 
sMRI, NP 
Ctx+: ↓ GM, ↓ NP; GM correlated with 
NP 
Kesler et al. [57] 42 Ctx+, 35 HC 4.8Y 
sMRI, INF, 
NP 
Ctx+: ↓ GM, NP, ↑ INF; ↓ GM 
correlated with INF 
Koppelmans et al. 
[14] 
184 Ctx+, 368 HC 21Y sMRI Ctx+: ↓ TBV, GM 
Koppelmans et al. 
[63] 
187Ctx+, 374 HC 21Y DTI 
Ctx+: WM integrity correlated with time 
since treatment; no change vs. HC 
Hosseini et al. [60] 37 Ctx+, 38 HC 4.5Y sMRI 
Ctx+: ↓ GM connectivity, organization, 
integration  
Bruno et al. [7] 34 Ctx+, 27 HC 5.35Y fMRI, SR 
Ctx+: ↑ SR, ↓ global cluster, nodal 
degree, hubs 
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de Ruiter et al. [9] 
17 HD Ctx+, 15 
Ctx- 
>9Y 
DTI, sMRI, 
NP, SR 
Ctx+: ↑ SR, ↓ NP, GM, focal FA;↑ MD 
correlated with ↓ neural markers 
Conroy et al. [8] 24 Ctx+, 23 HC 3-10Y 
s/fMRI, NP, 
SR, Comet 
Ctx+: ↓ GM, WMem activation, NP; GM 
correlated with PCI, NP, activation 
correlated with PCI, SR, OD 
Ctx+=survivors treated with chemotherapy, Ctx-=survivors not treated with chemotherapy, 
HC=healthy controls, Y=year, M=month, HD=high dose, sMRI=structural MRI, fMRI=functional 
MRI, DTI=diffusion tensor imaging, O-15 PET=Oxygen-15 positron emission tomography, FDG-
PET=18F Fluorodeoxyglucose positron emission tomography, Comet=assay of oxidative DNA 
damage, OD=Oxidative DNA damage, NP=neuropsychological testing, SR=self-report cognitive 
complaints assessment, ↓=decrease, ↑=increase, GM=gray matter, WM=white matter, 
WMem=working memory, CBF=cerebral blood flow, PS=processing speed, FA=fractional 
anisotropy, MD=mean diffusivity, VDM=verbal declarative memory task, EF=executive function, 
EMem=episodic memory, TBV=total brain volume, INF=Serum inflammatory cytokine levels 
a. PCI=post-chemotherapy interval; when one number is listed, this is the average length of time 
post-treatment. b. 10 breast cancer, 2 lymphoma survivors 
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The major endpoints of these studies were cerebral structural and activation 
changes. GM and WM damage consistently were reported in survivors except for 
Yoshikawa et al. (2005). This discrepancy may be explained by unique cohort 
characteristics such as ethnicity, since the majority of studies were conducted 
with Caucasian patients and this study only included Japanese individuals [67]. 
Authors of three studies reported association of these changes with increased 
cognitive complaints or decreased neuropsychological test performance [6,8,11]. 
Results from all six functional studies demonstrated activation or metabolic 
changes in survivors [8,10,13,59,62,66]. The direction of activation change 
seems to be task-dependent. In two studies activation change was found to be 
correlated with increased cognitive complaints [8,13]. Importantly, in two studies 
de Ruiter and colleagues found treatment-related cognitive alterations almost a 
decade after treatment, accompanied by lower neuropsychological test 
performance and increased cognitive complaints [9,10]. Koppelmans et al. (2012, 
2014) conducted two studies with a very large survivor cohort over 20 years post-
treatment. Findings included decreased brain volume, GM, and decreased WM 
integrity with increasing time since treatment, supporting the idea that breast 
cancer, treatment, or both are responsible for long-term possibly deleterious 
cognitive changes [14,63]. Results from all but one of these studies support the 
association of chemotherapy treatment with some measure of cognitive structural 
or function alteration which could lead to cognitive dysfunction. The majority of 
these findings are accompanied by neuropsychological testing deficits, increased 
self-reported cognitive complaints, or both, indicating the functional relevance of 
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these measures. However, more work is needed to discern which measures are 
specific to treatment and which to cancer. 
D. Pre-Chemotherapy Breast Cancer Studies 
Prompted by the need to discriminate between effects of breast cancer and 
treatment, three imaging studies were designed specifically to examine the 
influence of breast cancer on cognition (Table 2) [2,4,5]. Breast cancer patients 
were examined before treatment and compared to HC with fMRI during 
neuropsychological tasks. Activation decrease was observed for patients during 
response inhibition and working memory tasks, while activation increase was 
observed during a visuospatial task. Interestingly, two studies by Scherling et al. 
(2011, 2012) were performed in the same cohort using different tasks and found 
evidence that activation increase or decrease may be dependent on the type of 
task. These activation changes were not associated with test performance 
changes, suggesting that they may be compensatory [4,5]. This lack of 
association suggests that while breast cancer does appear to influence cognitive 
activation, the effects may vary depending on the cognitive process being 
assessed. Activation also may be a more sensitive measure of change than test 
performance.   
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Table 2. Pre-Chemotherapy Breast Cancer Neuroimaging Studies 
Study Cohort Method Results 
Cimprich et al. [2] 
10 PC, 9 
HC 
fMRI 
PC: ↓ speed, accuracy for verbal WMem task, ↑ 
activation 
Scherling et al. [4] 
23 PC, 23 
HC 
fMRI 
PC: ↑ activation during VS task, ↓ reaction time, 
errors 
Scherling et al. [5] 
23 PC, 23 
HC 
fMRI 
PC: ↓ activation during RI task, no performance 
change  
PC=cancer patients who have not yet received chemotherapy, HC=healthy controls, 
fMRI=functional MRI, ↓=decrease, ↑=increase, WMem=working memory, VS=visuospatial, 
RI=response inhibition 
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E. Longitudinal Breast Cancer Treatment Studies 
The existing longitudinal studies particularly are helpful in differentiating 
cancer and chemotherapy effects, especially as four of the six studies reviewed 
included Ctx- and HC (Table 3) [15-17,58,64]. Pre-treatment measures for all 
patients also allow discrimination of cancer and chemotherapy effects over time. 
Results of all six studies demonstrated some cerebral changes in cancer patients 
compared to controls, and results of the five studies with Ctx- controls indicated 
that some of these changes are specifically attributable to chemotherapy, while 
others appear to occur in cancer patients regardless of treatment. These findings 
suggest that while cancer patients experience cognitive alterations, 
chemotherapy may have independent effects. Thus Ctx+ patients may 
experience increased alterations compared to Ctx- patients, and may be at 
increased risk for cognitive sequelae. Two studies were designed to investigate 
effects of cancer and chemotherapy more than four months post-treatment with 
Ctx+, Ctx-, and HC groups. Findings included independent cancer and treatment-
related activation and GM changes post-treatment [16,17]. At one year post-
treatment, some activation changes still were observed in Ctx+ and Ctx-, and GM 
decrease was not fully recovered in Ctx+ patients, indicating that structural and 
functional changes can persist for significant periods of time.    
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Table 3. Longitudinal Breast Cancer Neuroimaging Studies 
Study Cohort Measures Method Results 
McDonald et 
al. [15] 
17 Ctx+, 12 
Ctx-, 18 HC 
BL, 1M, 
1Y 
sMRI 
Ctx+ & Ctx-: ↓ GM from BL to 1M 
Ctx+: some changes persist at 1Y 
McDonald et 
al. [16] 
16 Ctx+, 12 
Ctx-, 15 HC 
BL, 1M, 
1Y 
fMRI 
Ctx+ & Ctx-: ↑ frontal, ↓ left parietal BL 
WMem activation, 1M ↓ frontal activation, 
1Y partial recovery 
Ctx+: ↑ frontal activation at BL, 1M, 1Y 
McDonald et 
al. [17] 
27 Ctx+, 28 
Ctx-, 24 HC 
BL, 1M sMRI, SR 
Ctx+: ↓ GM at 1M; ↑ SR correlated with ↓ 
GM 
Ganz et al. 
[12] 
49 Ctx+, 44 
Ctx- 
8.7MD, 
14.7MD, 
20.7MD 
SR, NP, 
FDG-PET, 
INF 
Ctx+: 8.7MD ↑ SR, ↑ INF, INF correlated 
to inferior frontal metabolism; longitudinal 
↓ INF correlated to ↑ SR 
Deprez et al. 
[58] 
34 Cxt+, 16 
Ctx-, 19 HC 
BL, 3-4M DTI, NP 
Ctx+: ↓ NP at 1M vs. BL; NP correlated 
with ↓ FA 
Lopez Zunini 
et al. [64] 
21 Ctx+, 21 
HC 
BL, 1M fMRI, NP 
Ctx+: ↓ VMem activation at BL, 1M vs. 
BL 
Ctx+=survivors treated with chemotherapy, Ctx-=survivors not treated with chemotherapy, 
HC=healthy controls, BL=baseline (pre-chemotherapy), M=month post-treatment, MD=month 
post-diagnosis, Y=year post-treatment, sMRI=structural MRI, fMRI=functional MRI, SR=self-
report cognitive assessment, FDG-PET=[F-18] Fluorodeoxyglucose positron emission 
tomography, INF=inflammatory markers, DTI=diffusion tensor imaging, NP=neuropsychological 
testing, ↓=decrease, ↑=increase, GM=gray matter, WMem=working memory, FA=fractional 
anisotropy, VMem=verbal memory 
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F. Non-Breast Cancer Studies 
As stated previously, there is a dearth of research on this topic in non-breast 
cancer cancers. Additionally, of the eight studies found (Table 4), three studies 
were focused on the correlation of metabolism with psychological factors instead 
of cognitive factors [68-75]. However, these studies are still informative given that 
depression and cognitive complaints previously have been linked [79]. These 
findings provide indirect evidence for association of brain metabolism with 
cognitive complaints. Interestingly, results of a study in a lung cancer cohort 
indicated that patients had increased metabolism pre-treatment, suggesting that 
cancer may have a transitory metabolic effect on the brain in lung cancer [69]. 
Results from another study of lung cancer indicated that patients had altered 
neurochemistry pre-treatment, further supporting the hypothesis that lung cancer 
may alter cerebral activity [68].  
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Table 4. Non-CNS, Non-Breast Cancer Neuroimaging Studies 
Study Cancer Cohort Design Method Results 
Tashiro et al. 
[75] 
Various 
19 PC, 
17 HC 
CrS FDG-PET Cancer: ↓ metabolism 
Tashiro et al. 
[73] 
Various 
1 PC, 19 
Ctx+/-, 10 
HC 
CrS 
FDG-PET, 
SR 
Cancer: ↓ metabolism 
Tashiro et al. 
[74] 
Various 
2 PC, 7 
Ctx+, 12 
Ctx-, 10 
HC 
CrS 
FDG-PET, 
SR 
Cancer: ↓ metabolism; metabolism 
correlated with depression 
Ctx+: ↓ posterior metabolism 
Tashiro et al. 
[71] 
Various 
4 PC, 3 
Ctx-, 1 
Ctx+ 
CrS 
FDG-PET, 
NKA, SR 
Cancer: Metabolism, NKA, and 
anxiety correlated 
Tashiro et al. 
[72] 
Various 
11 Ctx-, 
5 Ctx+ 
CrS 
FDG-PET, 
SR 
Cancer: Metabolism correlated 
with social desirability 
Kumano et al. 
[70] 
Various 
6 Ctx+, 
13 Ctx- 
Longitu-
dinal 
FDG-PET, 
SR 
Cancer: BL metabolism associated 
with depression change over time 
Golan et al. [69] lung 
18 PC, 
8CS, 11 L 
PC CrS FDG-PET PC: ↑ metabolism  
Benveniste et 
al. [68] 
lung 
17 PC, 
15 HC 
PC CrS 1H-MRS PC: ↓ Neural markers  
PC=cancer patients who have not yet received chemotherapy, Ctx+=cancer patients treated with 
chemotherapy, Ctx-=cancer patients not treated with chemotherapy, HC=healthy controls, 
CS=cancer survivors, L=individuals with benign lesions, CrS=cross sectional study design, FDG-
PET=[F-18] Fluorodeoxyglucose positron emission tomography, SR=self-reported 
cognitive/psychological measures, NKA=natural killer cell activity, 1H-MRS=Proton magnetic 
resonance spectroscopy, ↓=decrease, ↑=increase, BL=baseline, Cancer=individuals with cancer, 
regardless of treatment status or time 
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Six studies were conducted in a mixed cancer population. All were limited by 
the assumption that the cancer types included in the studies affect the brain in a 
similar manner, which may not be true [70-75]. Only one study was designed to 
investigate the effect of chemotherapy treatment on metabolism. Decreased 
metabolism in Ctx+ patients was found, demonstrating that other cancer 
populations do experience treatment changes [74]. Three studies in mixed 
cohorts of treated and untreated cancer patients found decreased metabolism 
associated with cancer, supporting the possibility of cancer-induced cerebral 
alterations in non-breast cancer patients [73-75]. However, in seven of the eight 
studies only FDG-PET imaging was used. Clearly, more research is needed to 
investigate other imaging types in these populations. Future work also should 
include longitudinal studies with Ctx+, Ctx-, and HC groups to identify cancer and 
chemotherapy-specific changes, and should control for cancer type, or focus on 
one cancer. 
G. Clinical Implications and Future Research 
Oncology nurses and other healthcare providers should understand the role 
neuroimaging can play in identifying cognitive changes associated with cancer 
and cancer treatment, as well as the impact of these changes on social 
relationships, everyday functioning and work ability [80]. Directions for future 
neuroimaging research are: (1) to elucidate cancer and treatment-related 
changes in more diverse cohorts; (2) to utilize a range of imaging methodologies, 
as most studies to date have been focused solely on MRI and fMRI; and (3) to 
23 
 
utilize neuroimaging in interventional cognitive research to establish efficacy as 
well as elucidate therapeutic mechanisms of action. 
H. Conclusion 
 Results from neuroimaging studies in breast cancer cohorts have provided 
solid evidence supporting a variety of cerebral structural and functional 
alterations associated with cancer and chemotherapy treatment. Evidence from 
breast cancer survivors suggests that some of these changes persist for years. 
Little imaging research has been conducted in other cancer types; however, 
preliminary studies support cancer-related cerebral metabolic changes. More 
research is needed to clarify the individual roles of cancer and treatment-related 
changes, especially in non-breast cancer populations. 
 
 
 
 
 
 
 
This chapter was modified from research printed in the journal Seminars in 
Oncology Nursing. 
Holohan KN, Von Ah D, McDonald BC, Saykin AJ (2013) Neuroimaging, Cancer, 
and Cognition: State of the Knowledge. Semin Oncol Nurs 29: 280-287. © 2013 
Elsevier Inc.  
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III. Altered Cerebral Blood Flow One Month after Systemic Chemotherapy 
for Breast Cancer: A Prospective Study Using Pulsed Arterial Spin Labeling 
MRI Perfusion 
A. Introduction 
Breast cancer treatment has made great strides, leading to an overall five-
year survival rate of 89% according to SEER [81]. Given this high survival rate, 
resulting side effects are an area of increasing concern. Cognitive dysfunction in 
particular has been associated with breast cancer, chemotherapy, radiation, and 
anti-estrogen treatments, underscoring the need to clarify the mechanisms of 
disease and treatment effects on cognition [3,82-94]. 
Neuroimaging has been used to measure structural and functional effects of 
cancer and chemotherapy treatment, including treatment-associated frontal gray 
matter density (GMD) decrease in breast cancer patients [15,17,61]. However, 
characterization of the full spectrum of cerebral alterations associated with 
chemotherapy is far from complete; one novel area of investigation is the effect 
of chemotherapy on resting cerebral perfusion using pulsed arterial spin labeling 
(PASL) magnetic resonance imaging (MRI). PASL is a noninvasive advanced 
technique capable of measuring blood flow by using magnetically labeled arterial 
blood water as an endogenous contrast tracer. This technique can provide 
quantitative, stable, and physiologically meaningful images [95]. It has been 
shown to be well-suited to longitudinal studies of cerebral perfusion in healthy 
and diseased individuals, or as a surrogate marker of metabolism [96]. Based on 
previous prospective breast cancer studies, observed GMD decrease post-
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treatment suggests the likelihood of accompanying hypoperfusion; however, 
patterns of increased and decreased activation observed during cognitive task 
performance post-treatment might indicate the presence of hyperperfusion as 
well [15-17,61,66]. To test these competing hypotheses, we conducted the first 
controlled prospective study of cerebral perfusion in breast cancer patients 
treated with (Ctx+) and without (Ctx-) standard-dose chemotherapy and healthy 
controls (HC) using PASL MRI. We predicted that the Ctx+ group would evidence 
statistically significant changes in brain perfusion compared to the HC and Ctx- 
control groups post-treatment, in response to or in order to compensate for 
chemotherapy-induced cellular, vascular, or other tissue damage, and that this 
change would correlate with cognitive performance. Additionally, we analyzed 
perfusion changes for associations with previously reported frontal GMD change 
to investigate the functional independence of these measures and underlying 
mechanisms [17].  
B. Methods 
Ethics Statement 
All participants gave written informed consent according to the Declaration of 
Helsinki under a protocol approved by the Indiana University Institutional Review 
Board.  
Overall Study Design 
This manuscript focuses on a subset of data from a prospective, longitudinal 
investigation of cancer and treatment-related cognitive effects which includes a 
comprehensive study protocol of neuroimaging, neurocognitive, and behavioral 
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assessments as well as biomarker investigation. Other aspects of this and a 
related cohort have previously been reported [15-17,97]. In brief, study 
participants include Ctx+ and Ctx- female breast cancer patients and 
demographically matched HC. For Ctx+ patients, all study measures were 
acquired at baseline (after surgery but before radiation, chemotherapy, and/or 
anti-estrogen treatment), approximately one month after chemotherapy treatment 
completion, and approximately one year later. These time points were chosen to 
allow examination of both sub-acute and longer-term effects of treatment, with a 
particular focus on the effects of chemotherapy. Ctx- patients and HC were 
studied at yoked intervals (see Table 5). In addition to the PASL and T1 
sequences examined for this report, the detailed MRI examination included 
PD/T2 and FLAIR structural sequences, working and episodic memory functional 
MRI tasks, magnetic resonance spectroscopy, and diffusion tensor imaging. 
Neurocognitive assessment included a targeted research battery with emphasis 
on episodic memory and executive functioning, as well as measures briefly 
assessing other neuropsychological domains (e.g., general intellectual ability, 
language, attention, processing speed, visuospatial and motor skills, etc.). Self-
report measures included demographic and medical information, treatment 
sequelae, self-perceived cognition, mood and anxiety, and diet and lifestyle 
factors. Finally, blood samples were acquired for routine labs, genetic analyses, 
and banked for future investigation of potential biomarkers. Blood work was 
typically acquired in the early morning, while other study measures were 
acquired over the course of one or two study visits depending on participant 
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preference. MRI scanning was conducted prior to cognitive assessment 
whenever possible, though timing of study measures varied depending on 
scheduling availability. 
Participants 
The study cohort consisted of 27 Ctx+ patients, 26 Ctx- patients, and 26 HC. 
Only patients with non-invasive (stage 0) or non-metastatic invasive (stages I, II, 
or III) disease were included; additional exclusion criteria for all participants 
included prior cancer, substance abuse, and other medical, neurological, and 
psychiatric risk factors which might affect cerebral structure or function, as 
described in McDonald et al. (2013) [17]. Based on these criteria, 213 individuals 
were determined to be ineligible during phone screening. Another 15 individuals 
were excluded after enrolling in the study due to subsequent determination of 
ineligibility (e.g., tissue expanders, claustrophobia, etc.), withdrawal, or loss to 
follow-up, and 18 more individuals were excluded from this analysis due to lack 
of relevant data or scan quality, yielding 79 eligible participants with required 
data.   
All Ctx+ patients were treated with common standard-dose chemotherapy 
regimens. Eight neoadjuvant chemotherapy patients’ baseline measures were 
completed before surgery as well as chemotherapy; these individuals did not 
differ significantly from the other Ctx+ patients for any demographic factors, 
depression, or anxiety. Patients were recruited via the Indiana University Melvin 
and Bren Simon Cancer Center recruitment core and affiliated clinical practices. 
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Demographically matched healthy controls were recruited via community 
advertisements. 
Demographic and treatment characteristics are summarized in Table 5. The 
Center for Epidemiologic Studies-Depression Scale (CES-D) and the State Trait 
Anxiety Inventory-State subscale (STAI-S) were used to measure depressive 
symptoms and anxiety at each visit [98,99]. Self-reported caffeine consumption 
on scan days was also obtained. Demographic and treatment variables were 
assessed for statistical significance using SPSS 19 (SPSS Statistics 19, IBM 
Corporation, Somers, NY), using ANOVA, general linear models, and Chi-square 
analyses as appropriate. 
MRI Acquisition 
Scans were acquired on a Siemens Tim Trio 3T whole-body MRI scanner 
using a 12-channel receiver-only head coil. Subjects were scanned in a 
conscious resting state with closed eyes. Cerebral perfusion measurements were 
obtained using a previously published scan protocol [95]. Briefly, a Q2TIPS PASL 
sequence using the PICORE labeling scheme was applied. Utilizing a 10 cm 
labeling region with 25 mm spacing from the distal edge of the labeled region to 
the image section, an adiabatic inversion pulse for labeling was followed by 
optimized inversion time delays TI1 = 700 ms and TI2 = 1800 ms, chosen so as 
to minimize intravascular signal intensity at 3T. Images were acquired using a 
gradient-echo single shot EPI readout, with acquisition parameters: TR/TE = 
3000/13 ms, FOV = 224 mm, and matrix = 64x64. The imaging region consists of 
16 contiguous ascending axial slices of 7 mm thickness. Each perfusion 
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measurement consists of 100 dynamic (50 control and label image pairs) plus 
one M0 image (the equilibrium brain tissue magnetization used to normalize the 
difference perfusion map) with a scan time of approximately 5 minutes. The 
scanner’s built-in 3D online prospective acquisition correction (PACE) was used 
to minimize head motion artifact during acquisition. A high resolution T1-weighted 
magnetization prepared rapid gradient echo (MPRAGE) image and a high 
resolution EPI whole brain scan were acquired for subsequent reference and 
normalization; T2-weighted and fluid attenuated inversion recovery (FLAIR) 
sequences were also acquired to examine for incidental pathology. 
Image Analysis 
PASL scan processing was performed using previously published methods 
[92]. In brief, labeled images were subtracted from matched control images to 
create a perfusion-weighted time series; these were used to create quantitative 
regional perfusion maps for each scan, which were normalized to Montréal 
Neurological Institute (MNI) space in SPM8 (Wellcome Department of Cognitive 
Neuroscience, London, UK), resampled to 2 mm3 voxels, and smoothed with a 
FWHM kernel of 6x6x8 mm. Image analyses in SPM8 were run with and without 
age at baseline and scan-day caffeine consumption as covariates given previous 
findings of perfusion variance [100,101]. However, inclusion of these variables is 
not shown as groups were balanced and these variables did not significantly alter 
any results.   
A general linear model approach was utilized to conduct statistical parametric 
mapping on a voxel-by-voxel basis in SPM8. To specifically examine perfusion in 
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gray matter, the Pick Atlas gray matter mask was used as an explicit mask in all 
analyses [102]. MRI image acquisition and analysis of GMD was performed as 
described in McDonald et al. (2013) [17].  
Baseline analyses using a random effects model were performed to identify 
voxels with initial perfusion differences between groups. Weighted contrast 
vectors were entered for each group in the design matrix as described in 
McDonald et al. (2013) [17]. To test for areas in which cancer patients showed 
hypoperfusion relative to controls at baseline, -1 was entered in the Ctx+ and 
Ctx- baseline columns, while 2 was entered in the control baseline column. 
Alternate directionality and other interactions were similarly tested. The voxel-
wise critical significance threshold (Pcrit) was set to 0.001 uncorrected, with a 
minimum cluster extent (k) of 100 voxels for this and subsequent tests to reduce 
noise.   
An unbiased F test of overall effects was performed to identify any statistically 
significant perfusion differences between groups and times. The cluster of voxels 
with the most significant perfusion difference was used to graph group-by-time 
contrast estimates and 90% confidence intervals. All groups were tested alone 
for perfusion change over time using weighted contrast vectors. Based on these 
results, the Ctx+ group was analyzed for perfusion increase over time relative to 
HC in an interaction model, also using weighted contrast vectors. 
Perfusion and Cognition Analysis 
Due to the small cohort size, we chose to investigate cognition utilizing an 
overall neuropsychological performance test score (global score), generated by 
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averaging scores for eight neuropsychological domains in a similar fashion as in 
Conroy et al. (2013) [8] and Ahles et al. (2008, 2010) [84,85]. To discern whether 
chemotherapy was associated with a change in cognition, global score change 
was assessed for association with treatment group in SPSS 19 using a one-way 
ANOVA. Based on the results, global baseline score was chosen for testing with 
Ctx+ perfusion change. We extracted baseline and post-treatment cluster scores 
for the right precentral gyrus (area of significant increase in Ctx+ compared to 
HC) using MarsBar in SPM8, and subtracted baseline from post-treatment scores 
to obtain a change score for each Ctx+ individual [103]. Ctx+ perfusion change 
scores were tested for Pearson correlation with global baseline scores in SPSS.   
Perfusion and GMD Change Association Analysis 
To test for association of GMD and perfusion, we compared the previously 
identified frontal GMD change clusters with the more regionally diffuse pattern of 
change observed for perfusion. Association was only tested in the Ctx+ group, 
since only this group had statistically significant changes in both measures. To 
analyze this association, we extracted the two frontal clusters where significant 
GMD decreases occurred after chemotherapy using MarsBar in SPM8 and 
averaged them to obtain one GMD measure for each subject at each time point 
[103]. The measures at baseline were subtracted from the post-treatment 
measures, yielding a change score for each individual. These GMD change 
scores were used as the covariate of interest in a multiple regression testing for 
association with whole brain perfusion change. Perfusion change was measured 
by subtracting PASL baseline scans from post-treatment scans using the ImCalc 
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utility in SPM8 to create new scans only including regions of change. After 
multiple regression association testing of frontal GMD change with whole brain 
perfusion change in SPM8, again using the Pick Atlas gray matter mask, positive 
and negative associations were analyzed. Covarying for age did not significantly 
alter the results and is not reported. To graph GMD and perfusion, statistically 
significant perfusion change clusters from the positive association were extracted 
using MarsBar and averaged to one change score per individual; these were 
plotted against the GMD change measure. One individual’s perfusion and GMD 
scores were more than three standard deviations below the mean. Inclusion/ 
exclusion of this individual’s scores did not alter the statistical significance of the 
findings, so these data points are excluded from the graphical presentation of the 
results. 
C. Results 
Demographic and Baseline Comparisons 
Ctx+ patients had significantly higher stage disease than Ctx- patients (X2 
=18.82, df = 3, P < 0.001), as expected given current treatment protocols, and 
most had not received either radiotherapy or hormone therapy by one month 
post-chemotherapy treatment. There were no other statistically significant 
demographic differences or group-by-time interactions with depression or anxiety 
symptoms (CES-D, STAI-S, Table 5). The second scan occurred on average six 
months after the baseline visit; interscan intervals did not differ significantly 
between groups (Table 5). Eight patients received neoadjuvant treatment; these 
individuals did not demonstrate statistically significant demographic differences 
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or group-by-time interactions with depression or anxiety symptoms compared to 
adjuvant Ctx+, Ctx-, or HC groups.  
Baseline comparisons indicated no significant between-group differences in 
perfusion.   
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Table 5. Breast Cancer Cohort Demographics 
Variable 
Ctx+ 
(N = 27) 
Ctx- 
(N = 26) 
HC 
(N = 26) 
Pa 
Age at Baseline (yrs.) 
49.9 (7.6), 
(36-69) 
52.0 (8.9), (31-
68) 
48.4 (10.1), 
(32-69) 
0.350 
Education (yrs.) 
15.4 (2.8), 
(10-20) 
15.4 (2.5), (11-
20) 
15.6 (2.1), 
(12-20) 
0.954 
Estimated Full Scale IQ (Barona Index) 
[104] 
110.1 (6.7), 
(89-117) 
111.1 (6.2), 
(98-117) 
111.2 (5.2), 
(99-116) 
0.760 
Handedness (R,L/Amb) 26,1 24,2 24,2 0.662 
White, Non-Hispanic 77.8% 88.5% 80.8% 0.588 
CES-D raw score: Baseline 
10.9 (9.7), 
(0-38) 
9.0 (8.8), (0-
34) 
7.2 (7.6), (0-
28) 
 
CES-D raw score: 1M 
14.6 (9.3), 
(2-33) 
9.8 (9.7), (0-
40) 
6.9 (7.0), (0-
25) 
0.216 
STAI-S raw score: Baseline 
35.1 (15.0), 
(20-78) 
28.9 (8.0), (20-
47) 
30.9 (10.2), 
(20-55) 
 
STAI-S raw score: 1M 
35.4 (12.4), 
(20-62) 
32.2 (13.0), 
(20-64) 
32.4 (12.4), 
(20-62) 
0.601 
Inter-scan interval (days) 
158.7 (68.9), 
(73-387) 
177.2 (72.2), 
(106,480) 
159.6 (28.0), 
(116-253) 
0.465 
Cancer stage: 0 (DCIS) 0 6   
Cancer stage: I 11 18  0.000 
Cancer stage: II 12 2   
Cancer stage: III 4 0   
Received radiotherapy 2 16  0.000 
On anti-estrogen therapyb: Baseline 0 1 TAM   
On anti-estrogen therapy: 1M 
1 ANA, 1 
TAM, 1 LET 
11 TAM, 1 
TAM/LEU, 4 
LET, 2 ANA, 1 
EXE, 1 RAL 
  
Chemotherapy Regimenc,d     
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DOX/ CYC/ paclitaxel 8    
DOC/ CYC 8    
DOC/ carboplatin 6    
DOC/ DOX/ CYC 2    
DOC/ cisplatin 1    
DOX/ CYC 1    
paclitaxel 1    
Values are Mean (Standard Deviation), (Range). Ctx+=breast cancer patients treated with 
chemotherapy; Ctx-=breast cancer patients not treated with chemotherapy; BL=baseline (post-
surgery, pre-treatment); 1M=one month post-chemotherapy treatment completion; CESD=Center 
for Epidemiologic Studies-Depression Scale; STAI=State Trait Anxiety Inventory-State subscale. 
a. P value for one-way ANOVA with treatment groups for age, education, IQ, handedness, 
ethnicity, interscan interval, and radiotherapy; group-by-time analysis with treatment group for 
CESD and STAI, Chi-square with treatment group for cancer stage. b. ANA = anastrozole; TAM = 
tamoxifen, LET=letrozole; EXE=exemestane; RAL=raloxifene; LEU=lueprolide acetate. 
c. Nine Ctx+ patients were also treated with trastuzumab, one was also treated with sunitinib, and 
one was also treated with bevacizumab. d. DOX=doxorubicin, CYC=cyclophosphamide, 
DOC=docetaxel. 
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Perfusion Change: Chemotherapy Group Hyperperfusion 
An F test across all groups and both time points indicated statistically 
significant perfusion change over time, primarily in the right hemisphere (Figure 
2, Table 6). The cluster of maximal change, located in the right postcentral gyrus, 
is presented for all groups and both time points (Figure 3). In this region, the Ctx+ 
group showed hyperperfusion at one month post-treatment relative to both 
comparison groups. 
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Figure 2. Group-by-Time Analysis (F Test). Surface rendering of perfusion 
differences from baseline to one month post-treatment for all groups (Pcrit<0.001 
uncorrected, k=100). Colored areas indicate statistically significant changes 
between groups and/or times; red to yellow color scale. 
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Table 6. Regional Perfusion Changes for the Overall F Test, All Groups by 
Times. 
xa ya za kb T Z PFWE-corrc 
Region description 
(for cluster peak) 
44 −24 56 437 8.32 4.87 0.009 R Postcentral G (BA3) 
16 −58 54 112 7.91 4.72 0.018 R Precuneus (BA7) 
48 −70 2 268 7.78 4.67 0.022 R M Temporal G (BA37) 
42 0 48 183 7.74 4.65 0.024 R Precentral G (BA6) 
-10 -46 50 264 6.39 4.10 0.217 L Precuneus (BA7) 
R=Right, L=Left, G=Gyrus, BA=Brodmann Area, I=Inferior, M=Middle, S=Superior 
a. MNI coordinates. b. Cluster extent. c. Peak-level p value 
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Figure 3. Maximum Perfusion Change. Right postcentral gyrus perfusion signal 
from overall F test graphed by group and time (Red bars indicate 90% 
confidence intervals (C.I.)). Key: BL=baseline, 1M=one month post-treatment. 
 
  
40 
 
To further elucidate group differences in change over time, each group was 
tested individually. Only the Ctx+ group had statistically significant perfusion 
change, demonstrating an increase in perfusion from baseline to one month post-
treatment, primarily in superior and posterior brain regions (Figure 4, Table 7).   
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Figure 4. Ctx+ Group Post-Treatment Hyperperfusion. Surface rendering of 
Ctx+ increase from baseline to one month post-treatment indicates that bilateral 
superior and posterior brain regions demonstrate hyperperfusion post-treatment. 
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Table 7. Regional Perfusion Changes for Ctx+ Post-Treatment Increase. 
xa ya za kb T Z PFWE-corrc 
Region description 
(for cluster peak) 
46 -22 56 673 5.32 5.09 0.012 R Postcentral G (BA3) 
32 -84 24 1464 5.20 4.98 0.000 R S Occipital G (BA19) 
66 -24 34 116 5.03 4.83 0.552 R Postcentral G (BA2) 
-14 12 -10 119 4.27 4.14 0.540 L Lentiform Nucleus 
-6 -86 26 425 4.26 4.14 0.059 L Cuneus (BA19) 
-6 -64 56 207 4.22 4.10 0.282 L Precuneus (BA7) 
-16 -94 -16 101 4.20 4.08 0.612 L I Occipital G (BA17) 
-54 -18 54 128 4.07 3.96 0.507 L Postcentral G (BA3) 
R=Right, L=Left, G=Gyrus, BA=Brodmann Area, I=Inferior, M=Middle, S=Superior 
a. MNI coordinates. b. Cluster extent. c. Peak-level p value 
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To determine how much of this increase was statistically significantly different 
than controls, we analyzed group-by-time interactions; results indicated that the 
Ctx+ group perfusion increased relative to HC specifically in the right precentral 
gyrus after treatment, indicating that these patients had resting state 
hyperperfusion discernible by MRI compared to controls (Figure 5, Table 8). 
Table 9 lists mean perfusion for both time points as well as perfusion change for 
the right precentral gyrus cluster. 
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Figure 5. Ctx+ Perfusion Increase Compared to HC. Surface rendering of 
Ctx+ increase compared to HC over time indicates statistically significant 
perfusion increase in Ctx+ in the right precentral gyrus post-treatment. 
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Table 8. Regional Perfusion Changes for Ctx+ Increase Relative to 
Controls. 
xa ya za kb T Z PFWE-corrc 
Region description 
(for cluster peak) 
40 -24 60 151 4.22 4.10 0.429 R Precentral G (BA4) 
R=Right, L=Left, G=Gyrus, BA=Brodmann Area, I=Inferior, M=Middle, S=Superior 
a. MNI coordinates. b. Cluster extent. c. Peak-level p value 
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Table 9. Right Precentral Gyrus Perfusion Group Means 
Variable 
Ctx+ 
(N=27) 
Ctx- 
(N=26) 
HC 
(N=26) 
Pa 
Cluster Perfusion: Baseline 
35.0 (10.7), 
(18.1-53.7) 
33.9 (13.3), 
(2.5-57.5) 
35.9 (10.4), 
(18.1-57.7) 
0.821 
Cluster Perfusion: 1M  
49.7 (18.9), 
(21.5-96.6) 
38.8 (16.5), 
(-2.6-81.7) 
33.9 (10.6), 
(12.8-56.8) 
0.002 
Cluster Perfusion: Changeb 
15.0 (16.7), 
(-9.6-57.2) 
4.9 (14.7), 
(-22.1-33.9) 
-2.0 (9.0), 
(-20.9-11.5) 
0.000 
Values are Mean (Standard Deviation), (Range). 1M=one month post-treatment 
a. Significance, one way ANOVA with treatment group. b. Change=1M – Baseline.       
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The eight neoadjuvant patients were not analyzed separately, as the study 
design was not powered to detect subgroup effects. However, in the 
neoadjuvant-treated participants the mean perfusion increase in the right 
postcentral gyrus was almost identical to that observed for the adjuvant Ctx+ 
participants and Ctx+ group as a whole. The three Ctx+ patients who received 
anti-estrogen treatment in this interval also displayed a post-chemotherapy 
perfusion increase, though there was insufficient power for a formal assessment 
of hormonal effects or interactions. Given that only two Ctx+ patients received 
radiotherapy treatment during this interval, this factor is also unlikely to contribute 
significantly to the observed variation. 
Chemotherapy-Associated Hyperperfusion and Cognition 
To clarify the clinical significance of this perfusion increase, we assessed 
perfusion change for correlation with cognitive performance. Change in the global 
neuropsychological test score from baseline to post-treatment was not 
statistically significantly different between groups, although all groups showed an 
increase over time likely attributable to practice effects (Table 10). In the Ctx+ 
group, baseline global score was negatively correlated (r = -0.629, P < 0.001) 
with right precentral gyrus perfusion change from baseline to one month (Figure 
6), indicating that individuals with lower baseline cognitive performance showed 
greater perfusion increase over time.    
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Table 10. Global Cognitive Performance 
Variable 
Ctx+ 
(N=27)a 
Ctx- 
(N=25)a 
HC 
(N=26) 
Pb 
Global score: Baseline 
0.1 (0.6),  
(-1.-1.3) 
0.2 (0.6),  
(-1.6-1.0) 
0.0 (0.7),  
(-1.7-1.0) 
0.8 
Global score: 1M  
0.2 (0.6),  
(-1.0-1.4) 
0.3 (0.6),  
(-1.3-1.3) 
0.2 (0.7),  
(-1.8-1.3) 
0.8 
Global score changec 
0.1 (0.2),  
(-0.2-0.9) 
0.2 (0.2),  
(-0.2-0.5) 
0.2 (0.2),  
(-0.1-0.8) 
0.6 
Values are Mean (Standard Deviation), (Range). 1M=one month post-treatment 
a. Due to missing neuropsychological data, a global score could not be calculated for one Ctx+ 
individual at 1M (1M Ctx+ N=26), as well as one Ctx- individual at either time point. b. 
Significance, one way ANOVA with treatment group c. Change=1M - Baseline 
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Figure 6. Ctx+ Baseline Cognitive Performance and Perfusion Change 
Correlation. Individual baseline global neuropsychological test performance (x-
axis) graphed with right precentral gyrus perfusion cluster (statistically significant 
increase in Ctx+ vs. HC from baseline to post-treatment) change from baseline to 
one month post-treatment, indicating a significant negative correlation of baseline 
cognition with perfusion change. 
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Perfusion and GMD Association 
Because the chemotherapy-associated perfusion increase was not located in 
the frontal regions where GMD decrease was observed by McDonald et al. 
(2013) [17], we hypothesized that these effects might be independent. When the 
frontal GMD decrease was analyzed for association with whole brain perfusion 
change, we observed that there were statistically significant regions of bilateral 
frontal and parietal perfusion change positively correlated with GMD change 
(Figure 7, Table 11), indicating that decreased frontal GMD was associated with 
lower perfusion in these regions (r = 0.553, P = 0.003). However, if the frontal 
GMD decrease was associated with the hyperperfusion observed in Ctx+ 
patients, we would expect to see significant negative association in the superior 
and posterior regions. In this analysis there were no statistically significant 
regions of negative association, supporting our hypothesis that these are 
independent effects.       
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Figure 7. Perfusion and GMD Positive Association. A) Surface rendering of 
positive association between frontal GMD decrease and bilateral frontal and 
parietal perfusion change; association does not overlap with regions of Ctx+ 
hyperperfusion. B) Frontal GMD decrease (x-axis) graphed with average of all 
positively associated clusters of perfusion change (y-axis); decreased GMD is 
associated with decreased primarily frontal perfusion. 
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Table 11. Regional Perfusion Changes for Ctx+ Perfusion and GMD Positive 
Association. 
xa ya za kb T Z PFWE-corrc 
Region description 
(for cluster peak) 
12 18 -24 578 10.13 6.33 0.006 R Rectal G (BA11) 
-50 -60 -22 153 9.71 6.20 0.317 L Fusiform G (BA37) 
44 48 -10 136 8.26 5.68 0.377 R M Frontal G (BA11) 
-4 50 -24 285 7.61 5.43 0.084 L Rectal G (BA11) 
22 44 50 513 7.34 5.31 0.011 R S Frontal G (BA8) 
-42 -58 44 248 7.20 5.25 0.120 L I Parietal Lobule (BA40) 
34 -40 56 264 6.85 5.09 0.103 R Postcentral G (BA40) 
-8 58 40 255 6.71 5.03 0.112 L S Frontal G (BA9) 
-38 42 38 189 6.52 4.49 0.219 L S Frontal G (BA9) 
-48 -58 44 114 6.10 4.73 0.470 L I Parietal Lobule (BA40) 
38 64 12 608 5.92 4.64 0.005 R M Frontal G (BA10) 
24 -10 -12 121 5.74 4.54 0.439 R Amygdala 
-22 -8 0 159 5.07 4.17 0.298 L Lentiform Nucleus 
R=Right, L=Left, G=Gyrus, BA=Brodmann Area, I=Inferior, M=Middle, S=Superior 
a. MNI coordinates. b. Cluster extent. c. Peak-level p value 
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D. Discussion 
This is the first prospective, longitudinal study documenting the effects of 
chemotherapy on resting cerebral perfusion in breast cancer patients. Given 
conflicting evidence from other measures of cerebral effects of chemotherapy, 
we investigated two competing hypotheses, chemotherapy-induced hypo or 
hyperperfusion. Although previous evidence suggests that aspects of the cancer 
disease process and/or host factors in cancer patient may induce cerebral 
structural and functional alterations, in the present study there were no 
statistically significant between-group perfusion differences at baseline 
[2,4,5,8,16,17]. This initial observation suggests that breast cancer itself is not 
associated with changes in cerebral perfusion. Although requiring replication and 
possibly specific to the present cohort, the lack of baseline differences suggests 
that treatment-associated findings are unlikely to be confounded by cancer-
induced changes. This is important to note, as it may suggest that perfusion is a 
more specific indicator of cerebral alterations after chemotherapy, as other 
functional neuroimaging measures have shown differential alterations both prior 
to and after chemotherapy.     
Although perfusion and metabolism are normally coupled, a previous cerebral 
resting state metabolic study using fluorodeoxyglucose [18F] positron emission 
tomography (PET) by Silverman et al. (2007) did not find significant differences 
between control and adjuvant chemotherapy-treated groups, though they did 
identify a significant correlation between metabolism and the Rey-Osterrieth 
Complex Figure delayed recall performance in chemotherapy-treated subjects 
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[66]. They also found differential perfusion in Ctx+ group patients compared to 
controls during a functional [15O] PET study. Using functional MRI, McDonald and 
colleagues found differential activation in Ctx+ group patients, further supporting 
the idea that chemotherapy may alter perfusion and activation [16]. Thus it 
appears that PET and MRI may be complementary detection methods for 
perfusion and metabolic changes in response to chemotherapy. This new PASL 
data adds another perspective to prior findings, indicating that perfusion is 
altered in the resting state as well as during tasks, and may be related to 
previously identified metabolic, cognitive, and structural changes in breast cancer 
patients. 
To date, the precise mechanisms underlying chemotherapy-induced cognitive 
alterations are unknown. In addition to possible direct neurotoxic injury, several 
pathways that could influence cerebral structure and function have been posited 
as potentially affected by chemotherapy, including immune response, DNA 
repair, oxidative stress, and altered hormone levels or signaling, all of which may 
be genetically modulated [21,23,105]. Although only small amounts of 
chemotherapeutic agents have been measured in the brain, this may still be 
enough to provoke various cellular responses including inflammation and 
oxidative stress, less effective DNA repair, and possibly cell death, leading to 
structural and functional alterations and cognitive dysfunction [24-28]. All 
chemotherapy drugs utilized in this cohort are alkylating agents, anthracyclines, 
platinating agents, or taxanes; these antineoplastic agents target various aspects 
of DNA repair and cell cycle division, and cause apoptosis. A systemic response 
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to cell death could include several of the mechanisms listed above, and have 
widespread indirect cerebral effects, such as hyperperfusion. Interestingly, 
paclitaxel and docetaxel have been shown to have peripheral anti-angiogenic 
effects, and doxorubicin and paclitaxel have been associated with vascular 
toxicity [106-108]. Since all but one patient received paclitaxel or docetaxel, and 
only one patient in the Ctx+ group was on bevacizumab during the study, we 
could not draw any conclusions on the effects of anti-angiogenesis on perfusion; 
however, the individual receiving bevacizumab did experience increased 
perfusion post-treatment, consistent with other Ctx+ patients. The study was also 
not powered to examine any specific vascular toxicity related to doxorubicin or 
paclitaxel; this will be an important factor to consider in future studies. Although 
chemotherapy-altered estrogen signaling is still a possible causal mechanism, 
changes were likely not related to anti-estrogen treatments or aromatase 
inhibitors, since only three individuals out of 27 in the Ctx+ group were taking 
these types of medications at one month post-treatment [109]. Although this 
study was not powered to assess these individuals as a separate group, they did 
display hyperperfusion that was greater than that observed for the Ctx- or HC 
groups, though not as large as the Ctx+ group increase as a whole. Based on 
this evidence, we conclude that anti-estrogen or aromatase inhibitors are unlikely 
to contribute significantly to the observed hyperperfusion. Radiotherapy was 
similarly different between groups, with nearly all Ctx+ patients receiving this 
treatment following the one month post-chemotherapy time point, whereas the 
majority of Ctx- received radiotherapy before this time point. This emphasizes the 
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specificity of the chemotherapy effect on cerebral perfusion, as radiotherapy is 
unlikely to confound these results. Finally, caffeine consumption is known to 
influence cerebral blood flow. We only obtained general self-reported caffeine 
consumption on scan days, and so were not powered to do a detailed analysis of 
the variance accounted for by this measure; however, basic self-reported 
caffeine consumption was not significantly different between groups, suggesting 
that this was not a confounding factor for this analysis.  
Our observation that the statistically significant Ctx+ increase in cerebral 
perfusion was negatively correlated with baseline neuropsychological test 
performance suggests that baseline cognitive reserve may indicate an indirect 
protective mechanism; perhaps the Ctx+ post-treatment perfusion increase is an 
unsuccessful compensatory mechanism that is most pronounced in individuals 
with lower cognitive ability [85]. Future research should focus on identifying the 
biological mechanism driving the potential protective effect of baseline cognitive 
performance/reserve. 
The statistically significant pre- and postcentral gyri regions of chemotherapy-
associated cerebral perfusion increase reported here were independent of frontal 
GMD decreases noted in this cohort. However, bilateral frontal and parietal 
decreases in perfusion were observed that correlated with GMD decreases. 
These regional perfusion alterations may be influenced by different mechanisms. 
This is supported by previous investigations in AD suggesting that PASL and 
MRI GMD measures are complementary and have similar sensitivity; 
consequently if these measures were associated we would likely have detected 
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this in our study [110]. Assuming different mechanisms are involved, one reason 
for the lack of correlation could be the influence of individual demographic and 
risk factors on susceptibility; for instance, it may be that some individuals may 
have genetic polymorphisms impairing drug clearance, leading to toxicity, cell 
death, and hypoperfusion, while others are physiologically predisposed to 
inflammation, which might lead to hyperperfusion. The observed lack of 
association indicates that there are some individuals who experience both 
hyperperfusion and decreased GMD post-treatment; future studies should 
examine whether these two measures have additive relationships with cognitive 
performance or complaints, which may perhaps explain why only a subgroup of 
breast cancer survivors appear to experience long-term cognitive dysfunction. 
Further studies should also examine possible correlations of perfusion with 
other imaging methods, in order to further clarify the mechanistic basis of 
chemotherapy-induced cognitive alterations, with the long-term goal of 
developing preventative measures or treatments targeting these effects. While 
some cognitive alterations have been observed in survivors of breast cancer 
years after treatment, other studies show patient improvement by one year post-
treatment [15,16,30,85]. If brain changes such as those observed in this study 
persist, they may be contributing to long-term cognitive sequelae, prioritizing 
perfusion as a target for therapeutic measures [10]. Future studies should utilize 
multimodal imaging and long-term prospective designs to clarify the mechanistic 
basis and persistence of this adverse effect, to help determine the focus of 
therapeutic efforts and pharmaceutical intervention in this patient population. 
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Additional research could also use animal models to investigate the association 
of mechanisms such as direct neurotoxicity and immune response with 
neuroimaging measures; findings from such studies could provide important cues 
for therapeutic efforts. 
This first study of cerebral perfusion in a prospective cohort of breast cancer 
patients and healthy controls provides evidence that chemotherapy is associated 
with alterations in cerebral perfusion, independent of cancer effects. We found 
statistically significant hyperperfusion in superior and posterior regions after 
chemotherapy, which was not seen in patients who did not receive chemotherapy 
or controls. While this hyperperfusion was independent of frontal GMD decrease 
after chemotherapy, regional frontal and parietal hypoperfusion post-treatment 
did correlate with GMD decreases in these patients. The regional dissociation 
between hyperperfusion and GMD reduction suggests the involvement of 
independent functional mechanisms, as well as potential influence of individual 
risk factors, providing important information to guide future investigation towards 
therapeutic and preventative strategies. 
 
This chapter was modified from research printed in the journal PLoS One. 
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IV. Cerebral Perfusion and Gray Matter Changes Associated with 
Chemotherapy-Induced Peripheral Neuropathy (CIPN)  
A. Introduction 
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common, 
potentially permanent side-effect of breast cancer treatment [111,112]. However, 
despite various studies reporting changes in brain structure and function 
associated with other types of pain [113-118], the impact of CIPN on brain 
structure and function has not been well studied. To date, there has been only 
one publication on this topic, which compared multiple myeloma patients with 
CIPN to controls and found significant differences in CIPN-associated brain 
activation during pain processing [29]. The relationship between CIPN and 
cerebral perfusion has not been specifically studied to date but could be valuable 
in identifying future CIPN treatment targets. We hypothesized that CIPN 
symptoms (CIPN-sx) in breast cancer patients would be longitudinally associated 
with altered resting state cerebral perfusion. Additionally, in view of our previous 
observations of altered cerebral perfusion and gray matter density following 
breast cancer chemotherapy treatment [3,17,119], we investigated how these 
changes might relate to any CIPN-associated cerebral perfusion change.    
B. Methods 
Participants 
Written informed consent was obtained from all study participants using a 
protocol approved by the Indiana University Institutional Review Board in 
accordance with the Declaration of Helsinki. The female breast cancer cohort 
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used for this study has been extensively described in previous publications 
[17,119]. For the current analyses, the sample consisted of patients treated with 
(Ctx+, N=24) and without (Ctx-, N=23) common, standard-dose chemotherapy 
regimens. Data was collected at baseline, post-surgery and pre-chemotherapy 
treatment for most individuals. Eight patients received neoadjuvant 
chemotherapy; however, these individuals did not differ significantly from the 
other Ctx+ patients on demographic factors, depression, or anxiety. The same 
assessments were also collected one month (1M) post-chemotherapy treatment 
and one year (1Y) later (13 months post-treatment), with yoked intervals for Ctx-. 
Group sizes were smaller (Ctx+ n=18, Ctx- n=19) for 1Y analyses due to missing 
CIPN-sx data and participant exclusion (see below). Only patients with non-
invasive (stage 0) or non-metastatic invasive (stages I, II, or III) disease were 
included. Besides metastatic disease, additional exclusion criteria for all 
participants included prior cancer, substance abuse, and other medical, 
neurological, and psychiatric risk factors which might affect cerebral structure or 
function, as described in McDonald et al. (2013) [17]. 
Demographic and treatment characteristics are summarized in Table 12. The 
Center for Epidemiologic Studies-Depression Scale (CES-D) and the State Trait 
Anxiety Inventory-State subscale (STAI-S) were used to measure depressive 
symptoms and anxiety [98,99]. Between-group comparisons including ANOVA, 
general linear models, and Chi-square tests were run with SPSS 21 (SPSS 
Statistics 21, IBM Corporation, Somers, NY).  
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CIPN-sx were assessed using the self-report, validated FACT/GOG-Ntx 11-
item subscale [120]. Summed scores for each time point were generated. Given 
the specific nature of each included question, missing data was not imputed; if 
any question was unanswered, CIPN-sx total score was counted as missing. 
Exclusions from the cohort presented in Nudelman et al. (2014) comprised the 
following: for Ctx+, two individuals were missing baseline CIPN-sx, and an 
additional six individuals were missing 1Y CIPN-sx; for Ctx- two individuals were 
missing baseline or 1M CIPN-sx, and an additional four individuals were missing 
1Y CIPN-sx. Two additional individuals were excluded based on high baseline 
CIPN-sx: one adjuvant Ctx+ had CIPN-sx >4 standard deviations from the group 
mean at baseline, while one Ctx- with the highest CIPN-sx baseline score was 
noted to have a pinched nerve, requiring pain medication. Exclusion of these 
individuals yielded the final group sizes, presented above. Repeated measures 
ANOVA in SPSS were used to analyze CIPN-sx change over time. Additionally, 
ANOVA analyses at each time point contrasted CIPN-sx means between 
treatment groups. 
MRI Acquisition 
Cerebral perfusion scans were acquired with a Siemens Tim Trio 3T whole-
body MRI scanner using a 12-channel receiver-only head coil. During scan 
acquisition, subjects were in a conscious resting state with closed eyes. Details 
of the scanning protocol used to obtain cerebral perfusion measurements have 
been previously published [95]. Briefly, a Q2TIPS pulsed arterial spin labeling 
sequence was applied using the PICORE labeling scheme. Labeling was 
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performed with an adiabatic inversion pulse with a 10 cm labeling region and 25 
mm spacing from the distal edge of the labeled region to the image section, 
followed by optimized inversion time delays TI1 = 700 ms and TI2 = 1800 ms. 
These time delays were chosen to minimize 3T intravascular signal intensity. 
Images were acquired using a gradient-echo single shot EPI readout with 
acquisition parameters: TR/TE = 3000/13 ms, FOV = 224 mm, and matrix = 
64x64. The imaging region consisted of 16 contiguous ascending axial slices of 7 
mm thickness. Each perfusion measurement consists of 100 dynamic (50 control 
and label image pairs) plus one M0 image (the equilibrium brain tissue 
magnetization used to normalize the difference perfusion map), requiring a scan 
time of about 5 minutes. Head motion artifact was minimized using the scanner’s 
built-in 3D online prospective acquisition correction (PACE). High resolution T1-
weighted magnetization prepared rapid gradient echo (MPRAGE) images and 
high resolution EPI whole brain scans were acquired for subsequent reference 
and normalization. T2-weighted and fluid attenuated inversion recovery (FLAIR) 
sequences were acquired to check for incidental pathology. MRI scan acquisition 
for the analysis of gray matter density was conducted as previously described 
[17]. 
Image Processing 
Pulsed arterial spin labeling MRI scan processing was performed using 
previously described methods [95]. Briefly, matched control images were 
subtracted from labeled images to create a perfusion-weighted time series; the 
results were used to create quantitative regional perfusion maps for each scan, 
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which were normalized to Montréal Neurological Institute (MNI) space using 
SPM8 (Wellcome Department of Cognitive Neuroscience, London, UK). Scans 
were resampled to 2 mm3 voxels and smoothed with a 6x6x8 mm FWHM kernel. 
Image processing for MRI scans of gray matter density was performed using a 
previously described method [17]. 
Image Analysis  
To examine the potential roles of cerebral perfusion and gray matter in CIPN-
related pain processing, all imaging analyses were limited to the Ctx+ group. 
First, time point analysis was performed to test for association of cerebral 
perfusion at 1M and 1Y with CIPN-sx at 1M and 1Y, respectively. For each time 
point, whole brain perfusion scans were tested for association with the CIPN-sx 
variable using voxel-wise multiple regression imaging analysis in SPM8. A mask 
of regions of CIPN-sx-related perfusion at 1M was created for later use. 
Second, baseline to 1M longitudinal analysis was performed to test for 
association of cerebral perfusion changes with CIPN-sx. Perfusion changes (1M 
– baseline scan images, obtained using the ImCalc utility in SPM8) were tested 
for association with CIPN-sx at 1M covarying for baseline, using voxel-wise 
multiple regression imaging analysis in SPM8. CIPN-sx scores at 1M covaried for 
baseline were utilized to examine the relationship between perfusion change and 
symptom severity, controlling for variance related to higher baseline symptom 
report unrelated to chemotherapy treatment. Mean values for the cluster 
identified in this analysis were extracted using MarsBar, and 1M – baseline 
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values were computed in SPSS to obtain CIPN-sx associated perfusion cluster 
value changes for later use [102].  
Third, correlation analysis was performed for CIPN-sx and related perfusion 
changes with gray matter density frontal changes, reported in McDonald et al. 
(2013). Gray matter density frontal cluster values were obtained using MarsBar in 
SPM8, and 1M – baseline values were computed in SPSS to obtain cluster value 
changes. Gray matter density cluster value changes were tested using SPSS for 
Pearson correlation with baseline to 1M changes in both CIPN-sx scores and 
perfusion cluster values (obtained in the second imaging analysis). 
Fourth, image masking of the previously reported gray matter density-
associated frontal perfusion decrease observed in this cohort [119] was 
performed to determine whether it occurred in CIPN-sx-related regions identified 
in the first imaging analysis. Multiple regression analysis of perfusion changes 
(1M – baseline scans, as in the second imaging analysis) with gray matter 
density cluster value baseline to 1M changes in SPM8 was masked with 1M 
CIPN-sx-related perfusion (from the first imaging analysis).  
For the first three imaging analyses, to determine statistical significance and 
reduce noise, the voxel-wise critical significance threshold (Pcrit) was set to 0.001 
uncorrected, with a minimum cluster extent (k) of 25 voxels. For the fourth 
analysis, the voxel-wise critical significance threshold was relaxed to Punc. < 0.01, 
k=25, to identify any changes within the masked area. As presented in Nudelman 
et al. (2014), demographic and other confounding variables such as caffeine 
consumption were previously considered for their potential impact on imaging 
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analyses. These variables were not shown to be significant, and are not included 
in the current analyses.  
C. Results 
Demographic Analysis 
Comparison of treatment factors, including radiation, anti-estrogen, and 
chemotherapy, as well as cancer stage, identified significant group differences 
(Table 12); given current treatment protocols, these differences are typical for 
this type of study. At baseline, there were no significant differences between 
groups in terms of age, education, IQ, and race/ethnicity. Additionally, though a 
trend was observed for increased post-treatment depression in the Ctx+ group, 
there were no significant between-group differences for both baseline and 1M 
measures of depression and anxiety. Interscan intervals (approximately 5.5 
months for baseline to 1M, and 1 year for 1M to 1Y) did not differ significantly 
between groups. Finally, compared to adjuvant Ctx+ and Ctx-, the eight 
neoadjuvant Ctx+ did not demonstrate any significant demographic differences. 
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Table 12. Cohort Demographics and Treatment Data 
Variable 
Ctx+ 
(1M N=24; 1Y N=18 ) 
Ctx- 
(1M N=23; 1Y N=19) 
P-valuea 
BL Age 49.4 (7.9) 52.0 (9.1) 0.312 
BL Education 15.3 (2.9) 15.4 (2.3) 0.985 
BL Estimated Full Scale IQ 
(Barona Index) [104]  
109.9 (6.9) 111.2 (5.7) 0.501 
% white non-Hispanic 79% 91% 0.226 
BL CESD 9.2 (7.8) 7.3 (7.7) 0.392 
1M CESD 13.9 (8.4) 9.4 (9.6) 0.088 
1Y CESD 10.9 (7.5) 8.3 (9.9) 0.401 
BL STAI 33.4 (13.9) 27.8 (7.7) 0.098 
1M STAI 34.8 (12.0) 31.2 (12.7) 0.332 
1Y STAI 30.8 (8.2) 28.8 (9.4) 0.498 
BL to 1M interscan interval (days) 152.2 (63.1) 178.7 (74.1) 0.192 
1M to 1Y interscan interval (days) 379.5 (20.7) 371.8 (11.8) 0.170 
Cancer stage: 0 (DCIS) 0 5 0.002 
Cancer stage: I 11 16  
Cancer stage: II 9 2  
Cancer stage: III 4 0  
Received radiotherapy by 1M 2 15 <0.001 
Received radiotherapy by 1Y 11 12 0.020 
On anti-estrogen therapy at BLb 0 1 0.498 
On anti-estrogen therapy at 1Mb 3 16 <0.001 
On anti-estrogen therapy at 1Yb 8 15 0.033 
Chemotherapy regimen:c,d    
DOX/CYC/paclitaxel 7   
DOC/CYC 6   
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DOC/carboplatin 6   
DOC/DOX/CYC 2   
DOC/cisplatin 1   
DOX/CYC 1   
paclitaxel 1   
Values are mean (standard deviation) unless otherwise indicated. Ctx+=breast cancer patients 
treated with chemotherapy; Ctx-=breast cancer patients not treated with chemotherapy; 
BL=baseline (post-surgery, pre-treatment); 1M=one month post-chemotherapy treatment 
completion; 1Y=one year post-treatment completion (yoked interval for Ctx-); CESD=Center for 
Epidemiologic Studies-Depression Scale; STAI=State Trait Anxiety Inventory-State subscale. 
a. P value calculated for ANOVA or Chi-square analyses as appropriate. b. Anti-estrogen 
therapies included tamoxifen (majority), anastrozole, letrozole, exemestane, raloxifene, and 
lueprolide acetate. c. DOX = doxorubicin, CYC = cyclophosphamide, DOC = docetaxel. d. Eight 
patients were also treated with trastazumab, one was also treated with sunitinib, and one was 
also treated with bevacizumab.  
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Treatment Group CIPN-sx Analysis 
At baseline, CIPN-sx for Ctx+ and Ctx- were not significantly different (Table 
13). At 1M, Ctx+ reported significantly more CIPN-sx than Ctx- (P=0.006); 
however, at 1Y CIPN-sx levels did not differ significantly between groups 
(P=0.264). Repeated measures analysis of all three time points for the Ctx+ 
group showed that these patients experienced significantly increased CIPN-sx 
over time (P<0.001). In contrast, Ctx- CIPN-sx showed a non-significant increase 
from baseline to 1M (P=0.302), but repeated measures analysis over all three 
time points within this group demonstrated a significant increase (P=0.018). 
Finally, analysis of group differences in change of baseline to 1M CIPN-sx 
showed that Ctx+ increased significantly compared to Ctx- (P=0.001). 
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Table 13. Chemotherapy-Induced Peripheral Neuropathy Symptom  
(CIPN-sx) Change over Time 
Variable 
Ctx+ 
(1M N=24; 1Y N=18 ) 
Ctx- 
(1M N=23; 1Y N=19) 
Pa 
BL CIPN-sx 2.04 (2.6) 3.17 (3.5) 0.212 
1M CIPN-sx 9.75 (9.2) 3.87 (3.2) 0.006 
1Y CIPN-sx 8.89 (7.3) 6.47 (5.6) 0.264 
Pb <0.001 0.018  
CIPN-sx values are mean (standard deviation). Ctx+=breast cancer patients treated with 
chemotherapy; Ctx-=breast cancer patients not treated with chemotherapy; BL=baseline (post-
surgery, pre-treatment); 1M=one month post-chemotherapy treatment completion and 1Y=one 
year post-treatment completion (yoked interval for Ctx-).  
a. P value for ANOVA, between-groups at each time; b. P value for repeated measures ANOVA, 
within-group change over 3 time points. 
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Ctx+ CIPN-sx-associated Perfusion 
Time point analysis at 1M demonstrated that more CIPN-sx were associated 
with higher perfusion in several frontal region clusters, including the bilateral 
superior frontal gyri, bilateral medial frontal gyri, and left cingulate gyrus 
(Punc.<0.001; Figure 8, Table 14). However, at 1Y, analysis of CIPN-sx with 
perfusion did not demonstrate any significant associations. 
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Figure 8. Chemotherapy-Induced Peripheral Neuropathy Symptoms  
(CIPN-sx) Positively Associated with Perfusion. Surface rendering of the 
positive association of one month post-treatment perfusion with level of CIPN-sx 
reported at one month post-treatment (Punc.<0.001, k=25); colored regions 
indicate increasing statistical significance, as shown on the color scale to the 
right.  
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Table 14. Clusters of Significant* Cerebral Blood Flow (CBF)  
Test xa ya za kb T Z Pc BAd Region 
1M CBF, 1M CIPN-sx 4 18 56 231 6.21 4.67 0.031 8 R SFG 
1M CBF, 1M CIPN-sx 4 -28 70 73 5.02 4.05 0.199 6 R MFG 
1M CBF, 1M CIPN-sx -4 48 40 430 4.88 3.98 0.005 6 L MFG 
1M CBF, 1M CIPN-sx -6 0 62 60 4.79 3.92 0.243 6 L MFG 
1M CBF, 1M CIPN-sx -40 12 56 50 4.76 3.91 0.286 6 L MiFG 
1M CBF, 1M CIPN-sx -4 -14 32 40 4.18 3.55 0.340 23 L CG 
1M CBF, 1M CIPN-sx -30 22 54 37 4.07 3.48 0.359 8 L SFG 
1M CBF, 1M CIPN-sx 2 56 10 33 3.95 3.40 0.387 10 R MFG 
1M-BL CBF, 1M c BL CIPN-sx -16 22 40 37 4.12 3.49 0.329 32 L CG 
1M-BL CBF, 1M – BL GMD -40 10 58 38 5.06 4.13 0.566 4 L PCG 
1M-BL CBF, 1M – BL GMD -6 -22 40 90 3.22 2.91 0.364 32 L CG 
1M-BL CBF, 1M – BL GMD 4 16 54 64 2.92 2.67 0.447 8 R SFG 
*Chemotherapy-induced peripheral neuropathy symptom (CIPN-sx)-associated perfusion tests 
used voxel-wise Punc.<0.001, k=25; gray matter density (GMD)-associated perfusion tests used 
Punc.<0.01, k=25. BL=baseline (pre-surgery, post-treatment); 1M=one month post-chemotherapy 
treatment completion; 1M c BL = 1M covarying for BL; R=right; L=left; SFG=superior frontal 
gyrus; MFG=medial frontal gyrus; MiFG=middle frontal gyrus; CG=cingulate gyrus; 
PCG=precentral gyrus. 
a. MNI coordinates. b. k=cluster extent. c. Cluster-level uncorrected P values. c. BA=Brodmann 
area.  
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Longitudinal analysis indicated that more CIPN-sx at 1M, covaried for 
baseline, were also associated with increased perfusion from baseline to 1M. 
This increase was observed in part of a cluster identified in the 1M analysis, in 
the left anterior cingulate (Brodmann area 32; Figure 9, Table 14).  
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Figure 9. Chemotherapy-Induced Peripheral Neuropathy Symptoms (CIPN-
sx) Associated with Perfusion Increase. Colored regions of brain sections 
show areas with statistically significant association of baseline (post-surgery, pre-
treatment) to one month post-treatment perfusion increase and one month post-
treatment CIPN-sx covarying for baseline (Punc.<0.001, k=25). 
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Ctx+ Gray Matter Density Correlation 
Baseline to 1M gray matter density change was positively associated with 
both baseline to 1M CIPN-sx change and perfusion cluster change (Figure 10), 
indicating that individuals with more baseline to 1M gray matter density decrease 
did not tend to show increased perfusion and report increased CIPN-sx. 
Furthermore, gray matter density-associated perfusion decrease was observed in 
the right superior frontal gyrus and left cingulate gyrus, which were both 
observed in the previous CIPN-sx perfusion analyses (Figure 11, Table 14).   
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Figure 10. Gray Matter Density (GMD), Perfusion, and Chemotherapy-
Induced Peripheral Neuropathy Symptom (CIPN-sx) Change Correlations. 
A) Scatter plot of baseline (post-surgery, pre-treatment) to one month post-
treatment (1M) change in GMD frontal clusters (as seen in McDonald et al. 
(2013); x-axis) and CIPN-sx-associated perfusion cluster in the left cingulate 
gyrus (L CG). These variables showed a Pearson correlation r=0.582, P=0.004, 
as labeled on the fit line. B) Scatter plot of baseline to 1M change in GMD frontal 
clusters (x-axis) and CIPN-sx. These variables showed a Pearson correlation 
r=0.612, P=0.001, as labeled on the fit line. 
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Figure 11. Cerebral Perfusion Decrease Associated with Gray Matter 
Density Decrease in Regions of Interest. A mask of chemotherapy-induced 
peripheral neuropathy regions of interest superimposed on the analysis 
presented in Nudelman et al. (2014) of gray matter density frontal cluster change 
(baseline to one month post-treatment) with perfusion change, identifies clusters 
of gray matter density-associated perfusion decrease (P<0.01, k=25) in the 
cingulate gyrus (cross-hairs), and superior frontal gyrus. Colored areas of brain 
sections indicate areas of increasing statistical significance.  
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D. Discussion 
Compared to Ctx- patients, breast cancer patients treated with standard dose 
chemotherapy exhibited significant post-treatment CIPN-sx. Interestingly, the 
Ctx- group also displayed an increase in peripheral neuropathy symptoms over 
time, with the most significant symptoms observed 1Y post-treatment – perhaps 
in part due to post-treatment effects of other cancer drug types, including 
aromatase inhibitors, which can also produce neuropathy-like symptoms 
[121,122]. However, the specific increase of Ctx+ CIPN-sx immediately post-
treatment, when the majority of Ctx+ were not receiving anti-estrogen therapy 
(Table 12), suggests that the FACT/GOG-Ntx scale was specifically measuring 
chemotherapy-related symptoms at this time point. Additionally, the lack of 
increase in CIPN-sx from 1M to 1Y among women receiving chemotherapy 
suggests that anti-estrogen treatments did not contribute significantly to 
symptoms in this group. It should be noted that the majority of Ctx+ were not on 
anti-estrogen therapy at 1M, while the majority of Ctx- were; the longer average 
anti-estrogen treatment time for Ctx- might explain why this group showed an 
increase from 1M to 1Y in peripheral neuropathy symptoms, while the Ctx+ group 
did not.  
This is the first study to identify an association between cerebral resting state 
perfusion and CIPN-sx. In the Ctx+ group, a significant association was observed 
between post-treatment CIPN-sx and perfusion in brain regions previously 
associated with pain processing in other populations. Specifically, the anterior 
cingulate region is known to be involved in pain processing, and this effect has 
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been demonstrated in other pain populations and animal models [117,118,123-
128]. Preliminary evidence in the literature shows that therapies targeting this 
region may alleviate pain, suggesting a potential future intervention [129-131].  
Although a significant association between cerebral perfusion and CIPN-sx 
was identified at 1M, a similar association was not observed at 1Y, which may be 
partly due to a trend towards decreased CIPN-sx at this time. Alternatively, the 
changes in cerebral perfusion at 1M may reflect an acute pain processing 
mechanism, perhaps distinctly different from long-term chronic pain processing 
mechanisms. 
Given the previously reported results of frontal gray matter density decrease 
and associated perfusion decrease observed in this cohort [119], the impact of 
gray matter density change on CIPN-associated perfusion was also investigated. 
The association among gray matter density change, CIPN-sx, and perfusion 
change indicates that individuals showing gray matter density decrease may 
report less severe CIPN-sx while showing less CIPN-sx related perfusion 
change. This finding aligns closely with the recent finding that decreased gray 
matter density was associated with decreased perfusion in the left cingulate 
gyrus and right superior frontal gyrus [119], two regions where more CIPN-sx are 
associated with higher perfusion. This suggests that decreases in gray matter 
density may potentially interfere with CIPN-associated perfusion increase and 
reduce patient symptom report. This is particularly important because symptoms 
such as pain, numbness, and tingling are just one component of CIPN; deficits in 
motor reflexes, loss of dexterity, and issues with balance are also common. If 
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Ctx+ with gray matter density decrease do experience (and report) fewer 
symptoms compared to their non- gray matter density affected counterparts, it 
may mask identification and preclude intervention for potential threats to patient 
quality of life, occupational concerns, and CIPN-related safety concerns such as 
falls and accidents in the home, particularly in the elderly population.   
Several limitations to this study should be noted. First, although the study 
protocol asked participants to self-report CIPN-sx using a validated tool, the 
protocol did not include CIPN evaluation and grading by a clinician. While this 
information would have aided in clinical interpretation of the results and their 
implications, the FACT/GOG-Ntx has been shown to be sensitive to treatment 
differences and change over time [120], and is comparable to other currently 
used scales [132]. The association of CIPN-sx with perfusion change in known 
pain processing regions reported here provides some convergent validation for 
the FACT/GOG-Ntx. A related limitation of this study is the absence of objective 
peripheral assessments of CIPN (e.g., neurophysiological testing, skin biopsy); 
filling this knowledge gap will be vital to a more comprehensive understanding of 
CIPN-related neuroanatomical and functional changes.  
In summary, these results identify an objective neuroimaging perfusion 
measure associated with CIPN-sx. Identifying functional brain regions important 
to pain processing in this population may suggest future intervention targets for 
CIPN. Furthermore, these results suggest that gray matter density decrease and 
associated perfusion decrease may interfere with CIPN-sx-associated perfusion 
change and patient symptom perception – potentially clinically relevant findings, 
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as this could result in patient under-reporting of CIPN-sx. Future research should 
utilize objective peripheral measures of CIPN along with neuroimaging to further 
elucidate this mechanism and explore potential CIPN diagnostic and clinical 
implications. 
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V. Association of Cancer History with Alzheimer’s Disease Onset and 
Structural Brain Changes 
A. Introduction 
Multiple epidemiological studies have identified a significant inverse 
association between cancer and Alzheimer’s disease (AD), primarily in white 
non-Hispanic cohorts [37,38,40-42,133-135]. These studies provide convincing 
evidence that cancer history reduces the risk of AD in the white non-Hispanic 
population, with effect sizes ranging from 0.4 to greater than 0.6 [35,37-40]. 
Supporting the validity and specificity of this effect, a study by Roe et al. (2010) 
found the inverse association of cancer specific to AD as compared to vascular 
dementia. Another study by Musicco et al. (2013) identified the inverse 
association of cancer and AD in a very large population-based Italian sample 
accounting for physician and survival bias. This study of invasive cancer types 
found reduced relative risk of AD in subpopulations of breast, lung, bladder, 
prostate, and colorectal cancer survivors, though only the colorectal cancer 
subpopulation risk reduction was statistically significant. Interestingly, the 
cancers represented in most of these study populations were highly 
heterogeneous, suggesting that rather than specific cancer effects, such as 
estrogen deprivation in breast cancer, the inverse association between cancer 
and AD is likely due to strong underlying biological mechanisms. Identification of 
these biological mechanisms may provide direction to future therapeutic efforts, 
particularly for AD, as there is currently a significant lack of effective treatments 
for this disease. 
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There are many proposed mechanisms that may explain the inverse 
association of AD and cancer [36,136,137]; a common theory posits that it is 
primarily driven by genetic predisposition and molecular mechanisms either 
promoting or suppressing metabolic survival or apoptotic cellular pathways. This 
metabolic survival theory is supported by a recent paper by Ibanez et al. (2014), 
that identified genes differentially expressed in AD and several types of cancer 
concentrated in metabolic and genetic information processing pathways essential 
for cell survival and apoptotic regulation [138]. As regional neurodegeneration, 
including loss of gray matter density (GMD), is a hallmark of AD, it was 
hypothesized that if this theory is correct, older individuals with a history of 
cancer (CA+) would exhibit preserved GMD compared to those without cancer 
history (CA-), and that lower GMD in CA- would be related to earlier age of AD 
onset in contrast to CA+ individuals. 
However, cognitive and neuroimaging studies of breast cancer patients 
provide convincing evidence that CA+ survivors treated with chemotherapy have 
decreased GMD, more memory concerns, and worse neuropsychological test 
performance than CA-, up to 20 years post-treatment [14,15,17,30,139,140]. 
There is some evidence to support the negative impact of hormone therapies on 
perceived and objective cognitive function [92,141,142], and that radiotherapy 
may also be associated with cognitive dysfunction [143]. Furthermore, although 
the focus of this research to date has been on the effects of cancer treatments on 
brain structure and function, several studies of breast cancer patients have also 
found pre-treatment deficits in neuropsychological performance and brain 
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activation, suggesting that CA+ may be associated with cognitive dysfunction, 
independent of treatment effects [2,4,144]. Finally, as previously reviewed [3], 
there have been several imaging studies in heterogeneous cancer populations 
which have shown differences in brain activation compared to CA-, suggesting 
that these effects are not limited to breast cancer [68,69,73-75]. It has been 
suggested based on this evidence that cancer and treatment-related changes 
may be responsible for an accelerated aging process, particularly in subgroups of 
more vulnerable patients [83]. These results and line of reasoning predict that 
CA+ should experience greater cognitive dysfunction and neurodegeneration 
compared to CA-, which may actually worsen over time for some individuals. 
This growing body of cancer and cognition literature appears to be in conflict 
with the metabolic survival theory posited to underlie the inverse association of 
cancer and AD. To investigate this apparent contradiction, this cohort study 
utilized the Alzheimer’s Disease Neuroimaging Initiative dataset, comprising 
cognitively normal older adults (CN), participants with significant memory 
concern (SMC) in the absence of psychometric evidence of cognitive decline, 
older adults diagnosed with early and late mild cognitive impairment (MCI), and 
patients with mild clinical AD, to investigate the effect of cancer history on AD-
related neurodegeneration. We hypothesized that our findings in this 
independent sample would be consistent with previous research showing an 
inverse relationship of cancer and AD. However, also based on previous 
research, we expected to observe cognitive dysfunction and brain structural 
changes in cancer patients.  
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B. Methods 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
Data used in the preparation of this article were obtained from the ADNI 
database (adni.loni.usc.edu). ADNI was launched in 2004 as a collaboration 
including the National Institute on Aging (NIA), the National Institute of 
Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug 
Administration (FDA), pharmaceutical companies, and non-profit organizations. It 
was framed as a multi-year, public-private partnership, headed by Principal 
Investigator Michael W. Weiner, MD, VA Medical Center and UCSF. Many co-
investigators from over 50 sites across the United States (U.S.) and Canada 
have contributed to this longitudinal study, recruiting more than 1700 participants 
(aged 50-90) in three phases, ADNI-1, ADNI-GO, and ADNI-2.  
The ADNI study design is described briefly as follows. Participants were 
collected from across North American in three phases, ADNI-1, ADNI-GO, and 
ADNI-2; target participant numbers are listed in Table 15. This is not a population 
study, as the focus was on recruiting participants with specific AD-spectrum 
diagnoses. ADNI-GO and ADNI-2 added recruitment of early (EMCI) and late 
MCI (LMCI) to study the full spectrum of AD progression; these participants were 
all counted as MCI for the purposes of this analysis. As seen in Table 15, while 
ADNI-1 collected MRI, fluorodeoxyglucose (FDG) positron emission tomography 
(PET), and Pittsburgh compound B (PiB) PET, later phases of ADNI collected 
several additional types of neuroimaging data. All data phases collected 
neuropsychological and self-reported cognitive data, biological samples such as 
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blood for genetic analysis, and demographic and medical history data. 
Longitudinal protocols included data collection for each participant every six 
months for the first two years, and every twelve months after this point. Further 
information on ADNI study design, protocols, diagnostic criteria, and all 
measurements utilized in this analysis can be found at http://adni.loni.usc.edu/ 
and in previous reports [145-152]. Institutional Review Board approval was 
obtained by each ADNI site, and informed consent was obtained from each study 
participant or authorized representative. 
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Table 15. ADNI Study Design 
 Participants* Data Collection 
 CN EMCI MCI LMCI AD MRI fMRIa DTIb FDG AV45c PiB Biosd 
ADNI-1 200 - 400 - 200 X   X  X X 
ADNI-GO ↓ 200 ↓ - - X X X X X  X 
ADNI-2 150 150 ↓ 150 200 X X X X X  X 
Arrows indicate that study participants continued longitudinally in later phases of ADNI.  
a. fMRI=functional MRI. b. DTI=diffusion tensor imaging. c. AV45=florbetapir PET amyloid 
imaging. d. Bios=biological samples. *Numbers are study targets, not final statistics. 
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Participants 
Self-reported demographic information for all three ADNI phases included 
baseline age, education, sex, race, ethnicity, and handedness. These factors 
have all been previously associated with AD diagnosis [153-158], and as such 
were considered potential confounders; participants were excluded from this 
analysis if they were missing any of this information. Additionally, participants 
were genotyped for apolipoprotein E (APOE) ε2/3/4 alleles as described 
previously; since APOE ε4 is the major known genetic risk factor for late-onset 
AD and a potential confounder, participants were also excluded if they were 
missing this data [148,159]. All participants included in this analysis met ADNI 
inclusion and exclusion criteria, which have been described previously, and can 
be found at http://www.adni-info.org/ [150]. A general exclusion rule, as stated in 
the Procedures Manual, was that a history of any cancer other than non-
melanoma skin cancer (NMSC) within five years of screening was exclusionary. 
However, the manual also states that exceptions may be made on a case by 
case basis. Review of qualitative medical data indicated that there were 
exceptions made to this rule, primarily for individuals with prostate cancer, but 
also for individuals with other types of cancer which had been successfully 
treated and were in remission at the time of study enrollment. 
Participants were categorized at baseline as CN, SMC, MCI, or mild AD. 
More information on measures utilized in diagnosis is available on the ADNI 
website; basic diagnostic criteria are also briefly summarized as follows. Criteria 
considered include: subject, informant, and clinician report of memory concerns, 
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memory function documented by neuropsychological testing scores compared to 
education-adjusted cutoffs on the Logical Memory II subscale (Delayed 
Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale - Revised 
(maximum score=25), Mini-Mental State Exam score out of 30 [160], Clinical 
Dementia Rating (CDR, range 0-1) [161], and qualitative assessment by a 
physician of cognitive function and functional performance, guided by the 
NINCDS/ADRDA criteria [162]. CN participants show no signs of depression, 
memory complaints, MCI, or dementia; neuropsychological memory testing is 
within the normal range (>8 for 16 or more years of education, >4 for 8-15 years 
of education, or >2 for 0-7 years of education), they have a Mini-Mental State 
Exam score between 24 and 30, and have a clinical dementia rating (CDR) of 0. 
SMC individuals exhibit some forgetfulness; however, their informant does not 
indicate that they are consistently forgetful or experiencing progressive memory 
impairment. They score within the normal cognitive range for memory function, 
have MMSEs between 24 and 30, and have a CDR of 0. MCI individuals report 
subjective memory concerns, show abnormal memory function documented by 
neuropsychological testing (<9 for 16 or more years of education, <5 for 8-15 
years of education, or <3 for 0-7 years of education), have MMSEs between 24 
and 30, and have a CDR of 0.5; however, their general cognition and functional 
performance are sufficiently preserved such that a diagnosis of AD cannot be 
made by the site physician at the time of the visit. Finally, individuals with AD 
exhibit memory concerns, abnormal memory function documented by 
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neuropsychological testing, have MMSEs between 20 and 26, have CDRs of 0.5 
or 1.0, and meet NINCDS/ADRDA criteria for probable AD. 
As described in Saykin et al. (2010), APOE was genotyped using the two 
single nucleotide polymorphisms (SNPs) rs429358 and rs7412. A 3 mL sample 
of blood was taken in ethylenediaminetetraacetic acid (EDTA)-containing 
vacutainer tubes from all participants. Genomic DNA was extracted at Cogenics 
(now Beckman Coulter Genomics) utilizing the QIAamp DNA Blood Maxi Kit 
(Qiagen, Inc., Valencia, CA), following the manufacturer’s protocol. Polymerase 
chain reactions were used to amplify participant DNA, followed by HhaI 
restriction enzyme digestion, resolution on 4% Metaphor Gel, and visualization 
by ethidium bromide staining. 
Baseline age, education, sex, race and ethnicity (white non-Hispanic vs. all 
other reported races/ethnicities), handedness, and APOE ε4 status (0 ε4 alleles 
vs. at least 1 ε4 allele) were all analyzed for significant differences between 
cancer and AD diagnostic groups using Pearson Chi-square and ANOVA 
methods in SPSS 21 (SPSS Statistics 21, IBM Corporation, Somers, NY), to 
determine whether these potential confounders should be included in further 
analyses.  
Qualitative and quantitative self-reported medical history data was also 
obtained for all ADNI study participants. For the purposes of this analysis, all 
qualitative medical history data was manually curated to obtain a complete, more 
accurate account of each individual’s cancer history than was available based on 
quantitative data. All cancer types were considered for this analysis, including 
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NMSC. Medical information regarding cancer was broken down into pre-baseline 
cancer history (yes, 1, CA+; no, 0, CA-), as well as a count of prior cancer 
incidences. Reports of multiple NMSC were only counted as one cancer 
incidence, given the benign, prevalent nature of this cancer, as well as the lower 
quality of documentation regarding exact number of incidences. Cancer types 
were recorded and divided into 14 categories for analysis. Cancer types with only 
one incidence that did not fit any other categories were categorized as ‘Other’; 
notably, there were only seven of these cancer types, showing that the other 13 
categories represent the majority of observed cancer. Chi-square analysis of 
cancer categories by AD diagnostic group was performed to test for potential 
sample bias. Post-baseline cancer incidents were not utilized in this study due to 
the small number (43 total), which were distributed evenly between groups (Chi-
square χ2=4.054, p=0.256). 
MRI Acquisition 
MRI scans acquisition varied as part of the three ADNI initiatives. ADNI-1 
participants’ structural magnetic resonance imaging (MRI) baseline scans were 
acquired using 1.5 Tesla field strength; ADNI-2 and ADNI-GO both utilized 3 
Tesla field strength. All available baseline structural MRI scans were downloaded 
from LONI (http://adni.loni.usc.edu/) for included ADNI participants. Scans were 
corrected prior to download as previously described [145,163].  
Comorbidity Association Analysis  
Cancer history (CA+/CA-; prior to baseline) was analyzed for association with 
baseline AD diagnosis (four groups) using the Chi-square test. Post-hoc analysis 
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was also performed analyzing three types of cancer history, NMSC, prostate 
cancer, and breast cancer.  
Following these results, survival analysis was performed to analyze age of AD 
onset by cancer history. A time variable was created utilizing age of AD onset for 
participants diagnosed with AD before or during the study, and age at most 
current visit for all other study participants. To address potential sources of bias, 
this time variable was pre-adjusted for the following confounding variables 
identified in the demographic analysis: sex, education, handedness, 
race/ethnicity, and APOE ε4 allele status. A censor variable was used to denote 
AD (1) and non-AD (0) participants. Cox regression and Kaplan-Meier survival 
analyses were conducted utilizing these time and censor variables with CA+/- 
status as the factor of interest. Median age of AD onset and 95% confidence 
intervals (CI) were estimated using the Kaplan-Meier method, and Cox 
regression forward Wald tests were used to generate Chi-square statistics, 
significance, and odds ratios (OR), as well as graphical representations. A similar 
analysis using number of prior cancer incidences as the factor of interest was 
also conducted. Finally, post-hoc analysis investigated the association of the two 
most common cancer types, NMSC and prostate cancer, with pre-adjusted age 
of AD onset, using similar methods. Analyses were conducted using SPSS 21. 
Of the 1609 included study participants, 257 individuals converted to AD post-
baseline, bringing the AD group sizes for this analysis to 160 CA+ AD and 410 
CA- AD (total N=570), while CA+ (N=343) and CA- (N=696) included in other 
diagnostic groups were censored. For the AD cancer history number of 
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incidences analysis, 23 individuals out of the total 570 had a history of two 
cancers; no individuals with AD at baseline or individuals who converted to AD 
during the study had more than two prior cancers. 
Image Analysis 
Scans were processed for voxel-based morphometry (VBM) analyses in 
Statistical Parametric Mapping 8 (SPM8; Wellcome Department of Cognitive 
Neuroscience, London, UK), using an updated version of procedures described 
in previous reports [44,159,164,165]. The majority of participants had at least two 
scans from the baseline visit; the first acquired scan of acceptable quality was 
used. Briefly, scans were co-registered to a T1-weighted template, segmented 
into gray matter, white matter, and CSF compartments with bias correction, and 
normalized unmodulated to Montreal Neurologic Institute (MNI) space as 1 x 1 x 
1 mm voxels. Smoothing was performed with an 8 mm Gaussian kernel. 
Extensive quality control was performed on all scans. 1609 ADNI participants 
had all baseline demographic and medical data and baseline scans that passed 
all quality control measures.  
VBM analysis of GMD was performed in SPM8 to analyze differences 
between AD/cancer groups. The 1609 included participants were divided into 
eight groups based on AD diagnostic group and CA+/- status, and baseline 
corrected scans were analyzed for group differences using a full factorial model, 
covarying for potential confounding variables including study phase, field strength 
(1.5 Tesla or 3 Tesla), total intracranial volume (ICV), age, sex, education, 
handedness, race/ethnicity (white non-Hispanic vs. all else), and APOE ε4 allele 
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status. The SPM8 standard gray matter explicit mask was included in the model. 
Initial results suggested that this mask may not exclude some differences in 
white matter regions within the brain stem and cerebellum, likely noise caused by 
atrophy in the AD group; the SPM8 white matter exclusive mask was used to 
confirm that these changes occurred in white matter. 
Weighted contrast vectors were entered for each group in the design matrix to 
test hypotheses regarding differences in neurodegeneration across the eight 
AD/cancer groups. AD and MCI groups were expected to show greater 
neurodegeneration across large regions of the brain compared to other groups; 
to confirm this, a linear model of less GMD for each group further along the AD 
spectrum was applied (-2 for AD CA+/CA-, -1 for MCI CA+/CA-, 1 for SMC 
CA+/CA-, and 2 for CN CA+/CA-). The critical significance voxel-wise threshold 
(Pcrit) was set to 0.001 uncorrected, and the minimum cluster extent (k) for this 
contrast was set to 0; given the extensive GMD loss observed in AD and MCI, 
there was no correction for cluster size included. To test the hypothesis that 
cancer history was inversely associated with neurodegeneration, the model 
included weights of +1 for each CA+ group and -1 for each CA- group. CA+/CA- 
changes within each AD diagnostic group were considered in a similar fashion, 
and AD CA+/CA- were also contrasted with CN CA+/CA-. For each hypothesis, 
inverse models were also tested to confirm the specificity of the findings. The 
critical significance voxel-wise threshold (Pcrit) was set to 0.001 uncorrected, 
with a minimum cluster extent (k) of P≤0.1 uncorrected voxels for these 
contrasts. 
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For the significant cluster identified in the voxel-wise model of CA+ lower 
GMD across diagnostic groups, mean cluster GMD value was extracted for all 
individuals using MarsBar in SPM8 [103]. These values were analyzed and 
graphed in SPSS 21 to further investigate diagnostic group differences in GMD 
change. One outlier from the MCI CA- group with GMD greater than three 
standard deviations from the mean was excluded. These values were also 
analyzed with the General Linear Model Univariate ANOVA method, testing for 
association with types of cancer, covarying for demographic variables previously 
listed as well as baseline AD diagnostic group. Types of cancer tested included 
the four largest categories (NMSC, prostate, breast, and melanoma), as well as a 
category including all cancer types except NMSC. To test specifically whether 
non-malignant, non-invasive NMSC was associated with this effect, this cancer 
category was modified for this analysis to exclude individuals who had also had 
any other type of cancer (57 individuals excluded from 246).  
C. Results 
Demographic Analysis 
The 1609 individuals analyzed in this study were obtained as follows. 1818 
individuals had ADNI medical history files. Of these, 1780 also had pertinent 
demographic information (as listed in Table 16). Out of these individuals, 1609 
had quality-controlled MRI scans available for analysis.   
Demographic and disease characteristics of the cohort are summarized in 
Table 16. Age, sex, education, handedness, race/ethnicity, and APOE ε4 allele 
status were all significantly different between AD/cancer groups. There was a 
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significant, expected association between cancer history and smoking (Chi-
square χ2=4.2, P=0.024), but smoking only showed a trend for association with 
AD diagnostic groups (χ2=6.8, P=0.078), with a higher portion of SMC individuals 
reporting they had ever smoked. Since a higher portion of individuals with cancer 
were also SMC, the trend for smoking association is likely confounded by cancer 
history. Given this result, smoking was not included as a covariate in subsequent 
analyses. 
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Table 16. ADNI Total Cohort Demographics (N=1609) 
 
CA+  
CN 
CA-  
CN 
CA+ 
SMC 
CA- 
SMC 
CA+ 
MCI 
CA- 
MCI 
CA+  
AD 
CA-  
AD 
Pa 
 ADNI-1 75 135 0 0 108 258 45 133  
 ADNI-GO 0 1 0 0 50 78 0 0  
 ADNI-2 54 126 34 44 99 234 38 97  
 ADNI Total 129 262 34 44 257 570 83 230 <0.001* 
 Age 76(5.4) 74(5.9) 73(6.4) 71(4.8) 75(6.9) 72(7.8) 77(7.7) 74(7.8) <0.001+ 
 Education  15(3.3) 15(2.9) 16(2.8) 16(2.8) 17(2.5) 17(2.3) 17(2.5) 16(2.7) <0.001+ 
 % Male 68% 48% 68% 55% 53% 48% 61% 45% <0.001* 
 % R-Hand 97% 89% 88% 87% 88% 91% 92% 95% 0.037* 
 % White, NH 94% 81% 94% 87% 95% 88% 94% 88% <0.001* 
 % APOE ε4+ 29% 28% 38% 27% 49% 49% 60% 68% <0.001* 
 % Smoked 49% 35% 59% 50% 39% 40% 45% 36% 0.021* 
All included values collected at baseline; participants from ADNI-1 who continued in ADNI-GO or 
2 are reported as ADNI-1. Age and education values in years are mean (standard deviation). % 
R-Hand=% right handed. % White NH=% white non-Hispanic individuals. % APOE ε4+=% 
individuals with at least one APOE ε4 allele. % Smoked=% individuals reported ever smoking.  
a. P value for Pearson Chi-square(*) or ANOVA(+) with dependent variables listed and 
independent variable for treatment group/cancer history (eight groups, as shown). 
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Given that previous studies used highly heterogeneous cancer populations, 
the distribution of cancer types in ADNI was further examined. Out of the 1609 
individuals utilized in this analysis, there were 421 individuals with a history of 
one prior cancer, and 82 individuals with a history of multiple cancers, yielding 
593 total recorded cancer incidences. Cancer types were classified into 14 
categories, as shown in Figure 12 and Table 17. Although there are some 
differences in cancer distribution among groups, overall, cancer category 
percentages were not significantly different between diagnostic groups (Chi-
square χ2=31.2, P=0.8). Subsequent analyses investigating the inverse 
association of cancer and AD were therefore performed using all types of cancer 
unless otherwise stated. 
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Figure 12. Categorized Cancer Types Count out of 593 Total Incidences. 14 
categories were created from the original 40 cancer types. The “Other” category 
contained seven types of cancer with one reported case, which did not fit into any 
other category. GI, gastrointestinal cancer (including colorectal cancer); NMSC, 
non-melanoma skin cancer. 
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Table 17. Cancer Categories Count and Percentage by Diagnostic Group 
Cancer Category CN SMC MCI AD Total 
NMSC 74 (46.0%) 19 (48.7%) 123 (40.6%) 30 (33.3%) 246 (41.5%) 
Prostate 29 (18.0%) 4 (10.3%) 73 (24.1%) 24 (26.7%) 130 (21.9%) 
Breast 19 (11.8%) 5 (12.8%) 25 (8.3%) 9 (10.0%) 58 (9.8%) 
Melanoma 10 (6.2%) 5 (12.8%) 16 (5.3%) 7 (7.8%) 38 (6.4%) 
GI 9 (5.6%) 2 (5.1%) 22 (7.3%) 4 (4.4%) 37 (6.2%) 
Female Other 8 (5.0%) 1 (2.6%) 8 (2.6%) 6 (6.7%) 23 (3.9%) 
Glandular 3 (1.9%) 2 (5.1%) 12 (4.0%) 3 (3.3%) 20 (3.4%) 
Bladder 2 (1.2%) 1 (2.6%) 4 (1.3%) 3 (3.3%) 10 (1.7%) 
Renal 1 (0.6%) 0 (0.0%) 4 (1.3%) 2 (2.2%) 7 (1.2%) 
Lymphoma 2 (1.2%) 0 (0.0%) 3 (1.0%) 1 (1.1%) 6 (1.0%) 
Male Other 1 (0.6%) 0 (0.0%) 3 (1.0%) 0 (0.0%) 4 (0.7%) 
Oral 1 (0.6%) 0 (0.0%) 3 (1.0%) 0 (0.0%) 4 (0.7%) 
Leukemia 1 (0.6%) 0 (0.0%) 1 (0.3%) 1 (1.1%) 5 (0.5%) 
Other 1 (0.6%) 0 (0.0%) 6 (2.0%) 0 (0.0%) 7 (1.2%) 
Total 161 (100%) 39 (100%) 303 (100%) 90 (100%) 593 (100%) 
Values are expressed as count (percentage of cancer category out of total within each diagnostic 
group). “Other” category consists of cancer types that do not fit within another category; these 
included one each of the following cancer types: bone, chondrosarcoma, gallbladder, lung, 
meningioma, liposarcoma, and a foot tumor of unspecified origin. NMSC=non-melanoma skin 
cancer; GI=gastrointestinal. 
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In addition to baseline data collection, participants were also assessed at a 
number of follow-up visits, including visits at month(M)6, M12, M18, M24, M36, 
M48, M60, M72, M84, and M96. Though all other analyses concern data 
collected at baseline, longitudinal information on participant age and diagnosis at 
most current (latest) visit was downloaded on July 29, 2014 from the ADNI 
website (http://adni.loni.usc.edu/) for use in age of AD onset analyses discussed 
below. The numbers of participants at each most current visit were as follows: 
baseline (N=115), M6 (N=132), M12 (N=292), M18 (N=25), M24 (N=533), M36 
(N=223), M48 (N=49), M60 (N=26), M72 (N=52), M84 (N=101), and M96 (N=61). 
Because ADNI-GO and ADNI-2 are newer initiatives, participants in these 
phases of the study do not yet have visits beyond M48; data collection is 
ongoing. Of the 115 individuals with no visits beyond baseline, most participants 
withdrew voluntarily after this visit, for reasons including scheduling, discomfort 
or unwillingness to comply with protocols (particularly lumbar puncture), or 
partner/caregiver burden. There were 12 participants for whom there was no 
available data on reason for loss to follow-up, and an additional five participants 
who could not be contacted after the initial visit. Among the remaining 
participants with only baseline data, there were four participant deaths (three AD 
and one MCI), and seven participants who withdrew due to stated medical issues 
(two CN, four MCI, and one AD). Given the small number of participant 
withdrawals attributable to medical issues and death, it is unlikely that this is a 
source of bias for the longitudinal data analysis. 
AD and Cancer Inverse Association 
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Chi-square analysis indicated that CA+ was significantly associated with AD 
diagnostic group at baseline (χ2=9.4, P=0.025). As seen in Figure 13 and Table 
18, fewer study participants with AD are CA+ compared to other diagnostic 
groups. Interestingly, individuals with SMC are more evenly divided between CA+ 
and CA- than other groups.  
Post-hoc analysis examined the largest cancer category, NMSC, for 
association with AD diagnostic group. Chi-square analysis indicated that there 
were significantly fewer individuals with a history of NMSC in the AD diagnostic 
group (10%) compared to 15% or greater for all other diagnostic groups (χ2=16.9, 
P=0.001; Table 18), supporting inclusion of this cancer type in analyses. 
Interestingly, no such trend was observed for prostate cancer (χ2=1.8, P=0.61; 
Table 18). Breast cancer showed a trend for fewer individuals in the AD and MCI 
groups compared to SMC and CN, but this trend did not reach statistical 
significance (χ2=4.8, P=0.19; Table 18). Other cancer types were not examined 
due to insufficient power. 
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Figure 13. Percent of Individuals with Cancer History (CA+) per Diagnostic 
Group. There are significant differences in CA+ (blue striped bars) compared to 
individuals without cancer history (CA-, red dotted bars) between Alzheimer’s 
disease (AD) diagnostic groups (P=0.025), including cognitively normal controls 
(CN), and individuals with significant memory concerns (SMC), mild cognitive 
impairment (MCI), and AD. There is a smaller percentage of AD CA+, and a 
larger percentage of SMC CA+, compared to the CN CA+ percentage, while the 
MCI CA+/CA− ratio does not appear to be significantly different than CN 
CA+/CA−. 
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Table 18. Cancer History by Baseline AD Diagnostic Group 
 All Cancer Types NMSC Prostate Cancer Breast Cancer 
CA+ CA- CA+ CA- CA+ CA- CA+ CA- 
CN 
129 
(33%) 
262 
(67%) 
74 
(19%) 
317 
(81%) 
29 (7%) 
362 
(93%) 
19 (5%) 
372 
(95%) 
SMC 
34 
(44%) 
44 
(56%) 
19 
(24%) 
59 
(76%) 
4 
(5%) 
74 
(95%) 
5 (6%) 
73 
(94%) 
MCI 
257 
(31%) 
570 
(69%) 
123 
(15%) 
704 
(85%) 
73 (9%) 
754 
(91%) 
25 (3%) 
802 
(97%) 
AD 
83 
(26%) 
230 
(74%) 
30 
(10%) 
283 
(90%) 
24 (8%) 
289 
(92.3%) 
9 (3%) 
304 
(97%) 
Pa 0.025 0.001 0.610 0.190 
Values are expressed as count (percentage within diagnostic group). NMSC=non-melanoma skin 
cancer. 
a. P values for Chi-square analyses of each listed cancer type (or all) by diagnostic group. 
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Survival Analysis of Age of AD Onset 
Kaplan-Meier survival analysis of age of AD onset with cancer history 
indicated that those with CA- history had significantly earlier median age of AD 
onset, as seen in Figure 14A and Table 19; Cox regression shows that cancer 
history is protective against AD, with CA- 1.5 times more likely to develop AD 
compared to CA+ (P<0.001). Importantly, because this analysis was adjusted for 
APOE ε4, these results also suggest that cancer history-associated later age of 
AD onset is independent of this risk factor. Furthermore, this effect appears to be 
additive, as CA+ with one prior cancer are still 1.3 times more likely to develop 
AD compared to CA+ with two prior cancers (P<0.001; Figure 14B, Table 19). 
Post-hoc analysis of the two largest cancer categories indicated that CA+ 
NMSC showed the cancer protective effect against AD; CA- were 1.6 times more 
likely to develop AD compared to individuals with a history of NMSC (P<0.001; 
Table 19). A similar protective effect was also observed for prostate cancer, 
though this effect was not as significant (P=0.037; Table 19), possibly due to the 
smaller number of individuals with this cancer (see Table 17). 
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Table 19. Age of AD Onset (AoO) by Cancer History 
Method: Kaplan-Meier Cox Regression 
Measure: Median AoO 95% CI χ2 P AD OR  
All: CA- 81.7 80.7-82.8 
20.9 0.000 
1.5 
1.3-1.8 
All: CA+ 84.7 83.4-86.0 *Ref 
All: 0 CA- 81.7 80.7-82.8 
22.2 0.000 
2.0 1.3-3.0 
All: 1 CA+ 84.3 83.2-85.4 1.3 
0.9-2.1 
All: 2 CA+ 85.7 82.4-88.9 Ref 
NMSC: CA- 82.4 81.5-83.3 
13.3 0.000 
1.6 
1.2-2.1 
NMSC: CA+ 85.7 82.7-88.6 Ref* 
Prostate: CA- 82.8 82.0-83.7 
4.4 0.037 
1.4 
1.0-1.8 
Prostate: CA+ 84.7 82.6-86.9 Ref 
Values for Median AoO and 95% CI are given in years. AoO=age of onset; CI=confidence 
interval; AD OR=odds ratio of developing Alzheimer’s disease. *Ref=reference variable for odds 
ratio calculation. 
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GMD Differences between Groups 
As noted above, a linear model of GMD deficits in AD, MCI, and SMC groups 
compared to CN was used to confirm that groups further along the AD spectrum 
display lower GMD. As expected, lower GMD was observed for affected groups 
throughout the brain, consistent with prior work [164,165]. Modeling the opposite 
relationship, with higher GMD in the AD group compared to other groups, 
showed no significant regions of greater GMD in the AD group. A second VBM 
analysis examined all groups irrespective of AD diagnosis, to identify regions that 
were increased or decreased in CA+ compared to CA-. This model showed that 
CA+ had lower GMD in the right superior frontal gyrus compared to CA- (peak-
level Punc.<0.001, cluster-level Punc.≤0.1; Figure 15A). There were no regions of 
significantly greater GMD in CA+ at this threshold. As seen in Figure 15B, CA+ 
showed significantly lower GMD in the right superior frontal gyrus cluster across 
diagnostic groups. 
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Figure 15. Lower Gray Matter Density (GMD) with Cancer History across 
Diagnostic Groups. (A) Surface rendering shows individuals with a history of 
cancer (CA+) display lower GMD than individuals without cancer history (CA−), 
across diagnostic groups, in the right superior frontal gyrus (cluster maximum 
MNI coordinates 28, 32, 54), shown circled (Punc < 0.001, cluster threshold Punc ≤ 
0.1); this effect is observed to be bilateral at a more lenient threshold (Punc < 
0.01, cluster threshold Punc ≤ 0.1) as pictured. Colored areas indicate regions 
where CA+ gray matter density was less than CA− across groups at this 
threshold; red to yellow color scale indicates increasing statistical significance, 
with yellow areas indicating the most significant regions. (B) GMD values for right 
superior frontal gyrus cluster graphed by CA+ (red dotted bars) and CA− (blue 
striped bars) across AD diagnostic groups; CA+ have lower GMD across 
diagnostic groups. 
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This finding did not appear to be influenced by disease progression, as AD 
individuals did not display any significant differences compared to CN. 
Furthermore, comparing CA+ vs. CA- within each group did not yield any 
significant regions at this threshold. A lack of significant cortical and subcortical 
GMD differences between CA+/CA- within groups suggests that the lower CA+ 
frontal GMD is not being driven by any particular group, but rather is an 
underlying difference common to all CA+ in this study cohort. 
To further investigate this finding, GMD cluster values were tested for 
association with different types of cancer, controlling for AD diagnostic group and 
demographic variables. As expected, GMD was significantly associated with all 
cancer types (F=10.0, P=0.002), which was still significant after excluding 
individuals with NMSC (F=4.9, P=0.027). GMD was associated with prostate 
cancer (F=4.3, P=0.039), and showed a trend for association with breast cancer 
(F=3.7, P=0.055). Interestingly, GMD only showed a trend for association with 
NMSC (F=3.1, P=0.081), and showed no association with melanoma (F=0.0, 
P=0.916).  
D. Discussion 
These findings show a significant inverse association between cancer and 
subsequent development of AD in the ADNI cohort, in concordance with previous 
epidemiological studies. Importantly, while previous studies have indicated that 
this inverse association is mediated by age, our results are the first to quantify 
the later age of AD onset associated with cancer history, as well as to suggest 
that this effect may be additive, as the small group of individuals with a history of 
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multiple cancers showed later age of AD onset compared to individuals with a 
history of one or no cancers. Furthermore, these data demonstrated that NMSC, 
which has not been included in most other studies, was a significant driver of this 
effect. This suggests that the malignancy of the cancer may not be an important 
factor driving the inverse association with AD. Alternatively, it may highlight 
potential environmental mechanisms, such as sun exposure and subsequent 
increase in vitamin D. 
In order to obtain a more complete context for this analysis, cancer history 
data was compared to U.S. population-level cancer data using the SEER Cancer 
Statistics Review, 1975-2011 data for cancer incidence and 36-year limited 
duration prevalence. SEER data indicates that breast and prostate cancer are 
the most common cancer types (with very similar incidence and prevalence), 
followed by colorectal cancer and melanoma. However, this report did not include 
NMSC, which would be expected to have a higher incidence and prevalence 
(given that squamous and basal cell carcinomas are largely benign, noninvasive 
cancer types), as observed in the ADNI cancer history data. In ADNI, history of 
prostate cancer is more common than breast cancer, contrary to SEER incidence 
and first cancer prevalence. This is perhaps not surprising in this context, as 
prostate cancer has a later onset and thus may have a higher prevalence as a 
second or third cancer than other cancer types. Additionally, there may be more 
prostate cancer in the ADNI sample because there are more males with cancer 
participating in this study than females (65% male CA+). Accounting for these 
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demographic differences, the cancer history data in the ADNI cohort appears to 
be relatively similar to national incidence and prevalence estimates. 
There was one notable exception to the correspondence of ADNI data with 
the SEER national incidence data. Interestingly, there was only one reported 
case of an individual with a prior incidence of lung cancer in the 1609 individuals 
included in this study. This may be due to survival bias; although lung cancer 
incidence is quite common (comparable to SEER prostate cancer age-adjusted 
incidence in white individuals), lung cancer patients have very low SEER five-
year survival compared to other types of cancer (less than 20% for white men 
and women) [166]. 
There are a few other limitations of this study that are important to consider. 
Across diagnostic groups, CA+ individuals were, on average, older than CA-. 
This may represent an inherent study bias; given that CA+ individuals have a 
later age of AD onset, older CA+ than CA- would be expected in the AD group. 
However, it is interesting that this trend was also observed in other diagnostic 
groups, including CN. One possible explanation may be that in addition to later 
age of AD onset, CA+ individuals also experience later onset of age- or 
neurodegeneration-related memory concerns, which may be a motivator to enroll 
in this type of study. While this is an important caveat to keep in mind when 
interpreting the current results, the Kaplan-Meier survival analysis method, used 
to examine age of AD onset with all study participants, was chosen to minimize 
this limitation, and as noted above all neuroimaging analyses covaried for age. 
There were several other demographic differences between CA+/CA- groups; 
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CA+ had a higher percentage of white non-Hispanic individuals, likely due to the 
inclusion of all types of skin cancer in this category, and CA+ also had more 
males, likely due to the prevalence of prostate cancer in older men, as observed 
here. Again, all neuroimaging analyses covaried for these demographic 
confounds. The potential contribution of APOE ε4 to cancer was also considered; 
though APOE ε4 alleles are significantly different between diagnostic groups as 
noted in the demographics table, individuals with APOE ε4 alleles were not more 
likely to have cancer history than those without at least one APOE ε4 allele, and 
this factor was also covaried for in all neuroimaging analyses to account for its 
impact on neurodegenerative processes in AD. Age of AD onset analysis 
stratifying for APOE ε4 still found CA+ associated with later age of AD onset, 
supporting the assertion that APOE ε4 does not appear to be driving the inverse 
association of cancer and AD. 
The observed lower GMD in CA+ compared to CA- is not predicted by the 
common theory of the inverse association of cancer and AD, which suggests that 
CA- would have lower GMD. However, this finding does fit with studies in cancer 
patients, which have found gray matter reductions in patients undergoing 
treatment as well as long-term survivors up to 20 years post-treatment 
[14,15,17]. Additionally, in the present study an increased percentage of CA+ 
was observed in the SMC group compared to other groups, suggesting that while 
cancer may delay age of AD onset, CA+ individuals may have increased 
cognitive concerns, consistent with the cancer and cognition literature 
[17,21,31,34,167]. Interestingly, the frontal pattern of lower CA+ GMD occurs in 
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regions similar to those reported in neuroimaging studies of breast cancer and 
chemotherapy-associated gray matter changes [15,17]. 63% of cancers reported 
in ADNI were either NMSC or prostate; chemotherapy is not a common treatment 
for either of these, and chemotherapy is not administered for all patients afflicted 
with other types of cancer reported in this study, including breast cancer, the next 
most common cancer type. Therefore, while comprehensive treatment data were 
not available for these patients, it is probable that the majority did not receive 
chemotherapy. The CA+ effect observed here could be a synergistic result of 
cancer-specific changes in addition to a subgroup of patients experiencing 
chemotherapy treatment-related gray matter effects. The finding that lower GMD 
is significantly associated with invasive cancer types, and only showed a trend 
for association with NMSC, further supports this idea. These results highlight the 
need for more long-term studies of cancer and treatment effects on neuroimaging 
measures and cognitive dysfunction, particularly in older patients where these 
medical factors may predispose to neurodegeneration or pose an additional risk 
for cognitive dysfunction. 
Given the finding of lower GMD in CA+, which would be predicted in the 
context of cancer and cognition literature but is unexpected in the context of 
cancer and neurodegenerative disease literature, we posit that the inverse 
association of cancer and AD is more complex than the metabolic survival theory 
would suggest. As reviewed by Holohan et al. (2012), there are many potential 
pathways driving this effect, which may have synergistic interactions as well. 
Considering this information, we propose several alternate biological 
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mechanisms and highlight important directions for future research of this effect. 
First, while baseline imaging indicates lower GMD in CA+ patients, potentially as 
a long-term result of cancer and related treatments, this study does not capture 
the rate at which gray matter is changing over time in these patients. Examining 
this data will be an important step to confirm the neurodegenerative profile of 
CA+ compared to CA-. Second, analyzing the impact of cancer history on the 
amyloid pathway and associated biomarkers may demonstrate an alternate 
mechanism through which cancer could protect against AD. Given that high 
levels of inflammatory markers have been associated with poorer survival in 
cancer, cancer survivors may be selected for lower cytokine genetic load or 
expression, which may be protective against neurotoxic inflammation pathways 
linked to amyloid plaque accumulation in AD when compared to unselected 
individuals with no cancer history. It is also possible that some polymorphisms in 
the amyloid pathway may be inversely associated with cancer and AD; 
peptidylprolyl cis/trans isomerase, NIMA-interacting 1 (PIN1) has been proposed 
as one such candidate [168,169]. Finally, a common theory in the cancer and 
cognition literature posits that cancer patients and survivors have gray matter 
reductions and significantly increased subjective cognitive concerns, which are 
not well correlated with objective neuropsychological performance, potentially 
due to compensatory activation, wherein the brain recruits additional resources to 
deal with cognitive challenges. In the ADNI data there was a higher portion of 
cancer survivors in the SMC group, and cancer survivors had lower GMD than 
CA-; it is possible that these individuals experience compensatory activation, 
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similar to that previously shown in a functional MRI study of breast cancer 
patients, which may delay cognitive performance decline and AD diagnosis [16]. 
There are a multitude of pathways which have been implicated in AD and cancer, 
as discussed in Holohan et al. (2012), which require further functional 
investigation as well. Future research should investigate other biomarkers of AD, 
including longitudinal gray matter change, amyloid pathway-specific markers, and 
inflammatory markers, as well as measures of brain activation in cancer and AD 
diagnostic groups, to further elucidate the biological mechanisms underlying the 
inverse association of cancer and AD, with the goal of identifying preventative 
and therapeutic targets. 
 
 
 
 
 
 
 
 
This chapter was modified from research printed in the journal Frontiers in 
Physiology. 
Nudelman KNH, Risacher SL, West JD, McDonald BC, Gao S, Saykin AJ (2014) 
Association of Cancer History with Alzheimer’s Disease Onset and Structural 
Brain Changes. Front Physiol 5:423. © 2014 Nudelman et al.  
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VI. Functional MicroRNAs in Alzheimer’s Disease and Cancer: Differential 
Regulation of Common Mechanisms and Pathways 
A. Introduction 
Cancer and neurodegenerative disease have become prominent areas of 
medical research in the United States, as these diseases afflict millions of 
Americans each year. Since age is a major risk factor for each disease area, our 
aging population makes progress in treatment a high priority [81,170-172]. 
Fundamental hallmarks of cancer include uncontrolled proliferation and 
disruption of apoptosis; conversely neurodegeneration is associated with 
increased cellular death [173,174]. Therefore, both diseases may potentially 
result from differential regulation of the same cellular pathways. Supporting this 
hypothesis, negative epidemiological correlations have been demonstrated 
between cancer and neurodegenerative diseases including Down syndrome, 
Parkinson’s disease (PD), Alzheimer’s disease (AD), schizophrenia, and multiple 
sclerosis [43]. Interestingly, to date, although the rest of these neurodegenerative 
diseases appear to be associated with either increased or decreased comorbidity 
depending on the type of cancer, AD has been associated with a decreased co-
occurrence of all types of cancer. A recent large scale report indicated a 
significant negative correlation of cancer and AD in the Framingham Heart Study 
[37]. In a longitudinal study, patients with AD also had a lower risk of developing 
cancer after adjusting for demographic factors [40]. Further, Caucasian 
participants in another prospective study displayed a negative association 
between AD incidence and cancer risk [41].   
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MicroRNAs (miRNAs) comprise one major post-transcriptional regulatory 
mechanism that has been implicated in a variety of cancers and 
neurodegenerative diseases [175-180]. As illustrated in Figure 16, miRNA is 
generated as a long precursor sequence in the nucleus, where it is cleaved to 
form a shorter stem-loop precursor, transported to the cytoplasm, and further 
processed in the RNA-induced silencing complex (RISC) by the ribonuclease 
Dicer 1, ribonuclease type III (DICER1) into a very short (~22 nucleotide) double 
strand sequence; this is then unwound and one strand is loaded onto Eukaryotic 
translation initiation factor 2C, 2 (EIF2C2), which consequently inhibits translation 
or results in cleavage of target messenger RNAs (mRNAs) [181-187]. 
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Figure 16. MiRNA Generation and Function. The nuclear transcript pri-miRNA 
is several kilobases in length; this transcript is cleaved by the microprocessor 
complex (DCGR8 and Drosha), which yields a short (~65 nucleotide) stem-loop 
pre-miRNA. This is transported out of the nucleus by Exportin 5 (Exp5) to the 
RNA-induced silencing complex (RISC) and cleaved by DICER1 (targeting the 
hairpin loop), generating a ~22 nucleotide miRNA duplex; one strand is 
degraded, and the remaining strand is loaded into human immunodeficiency 
virus-1 transactivating response RNA-binding protein (TRBP)-recruited EIF2C2, 
also known as Argonaute 2, which then inhibits translation of target messenger 
RNAs (mRNAs) [181-187]. 
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The same miRNAs can be important to both types of disease; a few examples 
include miR-34b/c downregulation in PD and small cell lung cancer, upregulation 
of miR-206 as a protective effect against disease progression in a mouse model 
of amyotrophic lateral sclerosis and miR-206 downregulation in laryngeal 
squamous cell carcinoma, and miR-132 downregulation in frontotemporal 
dementia and methylation in prostate cancer [188-193]. To date, there has been 
a focus on miRNAs in cancer. Although the roles of miRNAs in 
neurodegenerative diseases have not been as thoroughly investigated, these are 
currently under increasing scrutiny [194]. Given the plethora of information on 
cancer regulatory mechanisms including miRNA, as well as the possible 
involvement of some of the same miRNAs in cancer and neurodegeneration, 
consideration of the roles of miRNA functions in cancer might help elucidate 
corresponding or opposing functions in neurodegenerative disease. A more 
comprehensive review of the roles of miRNAs in cancer and neurodegeneration 
might yield insights into the underlying pathways involved in these diseases. 
The full spectrum of roles of miRNAs in different types of cancer and 
neurodegenerative diseases is a rich topic but beyond the scope of this targeted 
review; we decided to focus our analysis on select miRNAs implicated in both AD 
and cancer. AD pathology is characterized by an accumulation of extracellular 
amyloid plaques composed of amyloid-beta peptide fragment (Aβ) and 
intracellular neurofibrillary tangles composed of hyperphosphorylated protein tau, 
as well as neuronal loss in the hippocampus, temporal, and frontal lobes, 
increased inflammation, and oxidative stress [195-201]. We will review a number 
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of studies linking miRNAs with differential expression and pathology in AD such 
as deposition of amyloid plaques and neurofibrillary tangles, as well as more 
specific pathway interactions and regulatory functions of the amyloid pathway, 
including regulation of amyloid protein precursor (APP) and beta-site APP 
cleaving enzyme 1 (BACE1), encoding a protease (β-secretase) that cleaves 
amyloid beta precursor protein to generate Aβ. The larger form of Aβ peptide 
containing 42 amino acid residues (Aβ42) mostly aggregates to form the 
previously mentioned amyloid plaques (see Figure 17).   
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Figure 17. MiRNA Involvement in the Amyloid Pathway Appears to 
Contribute to AD. BACE1 mRNA expression appears to be redundantly 
regulated by multiple miRNAs (including predicted miR-9, not shown); APP 
mRNA expression is also regulated by miRNA. More miRNA binding sites have 
been bioinformatically predicted for both mRNAs, indicating that this regulatory 
mechanism is most likely very tightly regulated [202]. Solid lines indicate known 
interactions; dashed lines indicate measured correlations. 
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We will focus on eight miRNAs (miR-9, -29a/b, -101, -107, -125b, -146a, -153, 
and -195) with differential expression in AD, evidence of correlation with disease 
pathology, and evidence of specific functional interactions, in order to investigate 
whether the large body of cancer research on these molecules may shed 
additional light on their function in AD, and whether it is also possible to use 
existing knowledge of these miRNAs in AD to further elucidate their functions in 
cancer. Serving as a case study of the potential utility of this type of cross-
disease comparison, we suggest that miRNA research in cancer may lead to 
hypotheses for novel roles of these miRNAs in AD, and highlight important 
directions for future research. 
We expect to observe miRNA involvement in cancer and AD in pathways that 
may be contributing to both pathologies, as well as activity in disease-specific 
pathways, and anticipate that the differential expression and or regulation of 
these miRNAs may contribute to the differences in disease pathology. In addition 
to the aforementioned proliferative / anti-apoptotic pathway, we expect to 
observe miRNAs involved in invasion, metastasis, inflammation, oxidative stress, 
and angiogenesis in cancer; since many of these pathways have also been 
implicated in neurodegeneration, we expect that these miRNAs will also be 
implicated in the same or related pathways in AD [43,203-211].   
For some pathways, including proliferation and pro-survival mechanisms, we 
expect to find evidence of inverse relationships [37,169,212]; however, for 
inflammation, oxidative stress, and angiogenesis it is reasonable to expect 
similar activity since these are known factors in both areas of pathology 
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[200,205,206,213-216]. Although there is evidence that the neuro-immune and 
inflammatory pathways are upregulated in AD, in cancer there is evidence that 
immunity can both suppress tumor growth and promote tumor progression, a 
process referred to as ‘immunoediting’ [205,217,218]. Figure 18 summarizes the 
documented and hypothesized roles of these pathways in cancer and AD. A 
comparison of miRNA expression and activity may yield more information on the 
contribution of these pathways to disease initiation and progression.   
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Figure 18. Molecular and Cellular Pathways Important to AD and Cancer. 
Increased levels of inflammation and oxidative stress have been positively 
associated with cancer and AD. Angiogenesis is considered one of the hallmarks 
of cancer, and has also been shown to be triggered by amyloid in AD [173,213]. 
Proliferation and pro-survival pathways have been shown to be positively 
associated with cancer and negatively associated with AD. Immunity has been 
shown to be both positively and negatively correlated with cancer 
(‘immunoediting’), in addition to being positively correlated with AD. The amyloid 
pathway does not appear to be involved in cancer pathways, so for the purposes 
of this review is specific to AD. Blue lines indicate interactions found in AD 
research; orange lines indicate interactions found in cancer research. 
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B. MiR-9 
Three studies found that miR-9 was significantly upregulated in the 
hippocampus and temporal lobe neocortex of AD brains compared to normal 
aging brains, indicating that miR-9 may play a pathological role in AD [219-221]. 
Because these brain regions show extensive pathology during the progression 
from health to AD [222-226] upregulation of miR-9 may play a role in 
degeneration. However, other studies found miR-9 was downregulated in the 
hippocampus, anterior temporal cortex and medial frontal gyrus in AD patients 
[227,228]. Therefore, at present there is conflicting data regarding the specific 
role of miR-9 in AD and its expression pattern in key cerebral regions and 
differences in sample characteristics and methods may be a factor in 
directionality of changes. It should be noted that miR-9 has a half-life of 30-60 
minutes; the post-mortem interval (PMI) for the three studies finding upregulation 
of miR-9 was 3 hours or less, while the other two studies had PMIs of 3-10 hours 
and 24 hours [220]. It seems possible that this variability is enough to explain the 
measurement discrepancies, in which case miR-9 is upregulated in AD brains, 
but decays at a rapid rate post-mortem, causing it to appear downregulated at 
later time points. 
 In terms of mechanism, miR-9 has been predicted to target the 3’ 
untranslated region (UTR) of BACE1, a key element of the amyloid pathway, 
though to our knowledge there is currently no functional evidence of this 
interaction. If confirmed, this would support miR-9 downregulation, presumably 
resulting in increased β-secretase activity and increased Aβ42 production [228]. 
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Finally, there is some initial evidence that miR-9 may be upregulated in response 
to interleukin-1Β (Il-1β) and Aβ42-induced Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 1 (NF-kappaB), implying that miR-9 may be 
involved in the AD inflammatory and oxidative stress pathways [229]. Brain-
enriched miR-9 has also been implicated in a wide variety of functions in different 
life stages and organisms; overexpression in adult mouse neural progenitor cells 
has been shown to facilitate neuronal differentiation, although inhibiting miR-9 
does not inhibit differentiation [230,231].   
MiR-9 is active in a variety of pathways, with both tumor suppressive and 
oncogenic functions for different types of cancer. Downregulation has been 
observed in metastatic melanoma and head and neck squamous cell carcinoma 
(HNSCC) [232,233], while upregulation has been observed in glioma, gastric 
cancer, biliary cancer, Hodgkin lymphoma (HL), colorectal cancer (CRC), breast 
cancer, and cervical cancer [234-241], indicating that this regulatory miRNA is 
likely involved in multiple pathways, some of which are differentially regulated in 
different cancer types. 
There is functional evidence that this miRNA may act as a tumor suppressor 
in some cancers. Cell proliferation was significantly inhibited in a HNSCC cell line 
by overexpression of miR-9, indicating that it may be a negative regulator of this 
pathway [233]. MiR-9 was also shown to downregulate proliferation and 
metastasis pathways in melanoma via the NF-kappaB1 molecular pathway; it 
was shown to directly target the NFKB1 3’ UTR. Since NFKB1 is known to be 
activated by inflammatory and oxidative stress signals, this indicates that miR-9 
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may play an important role in these pathways in cancer as well as AD 
[200,232,242]. MiR-9 is upregulated by NF-kappaB in AD, and downregulates 
NFKB1 in melanoma, suggesting that there may be a negative feedback loop in 
AD or differential regulation of this mechanism in AD and cancer. Additional 
research will be required to determine which of these explanations is correct.   
In contrast to the role of miR-9 in suppressing proliferation and metastasis, 
and possible involvement in the NF-kappaB inflammatory and oxidative stress 
pathways, other data indicate that miR-9 upregulates oncogenic pathways in 
cancer including proliferation, metastasis, and invasion. An investigation of 
glioma found that inhibition of miR-9 reduced tumor cell stemness and led to 
cellular differentiation [238]. It was also shown to increase cell motility, and 
overexpression downregulated α-catenin in CRC, indicating involvement in 
metastasis [241]. In breast cancer, miR-9 expression was upregulated in higher 
grade tumors, indicating that it may be involved in proliferation and or metastasis 
[235]. Involvement in these pathways is also supported by research in cervical 
cancer, where upregulation of miR-9 was associated with increased cellular 
viability, anchorage-independent growth, and migration in vitro [240]. In an 
endometrial cancer cell line, miR-9 was shown to significantly reduce expression 
of Forkhead box O1 (FOXO1), a transcription factor, while in another endometrial 
cancer cell line inhibition of this and several other miRNAs resulted in re-
expression of FOXO1, cell cycle arrest, and apoptosis [243]. Upregulation of 
miR-9 in HL results in repression of Hu antigen R (HUR; responsible for 
stabilizing messenger RNAs (mRNAs) to regulate gene expression) and DICER1 
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(a major regulator of mRNA, see Figure 16), leading to increased cytokine 
production by HL cells and attraction of normal inflammatory cells, indicating that 
miR-9 may be involved in large-scale translational regulation as well as 
inflammation pathways [236,237].   
There is conflicting evidence regarding the function and expression of this 
miRNA in AD and cancer, making interpretation of its roles challenging. MiR-9 
has been found both up- and down-regulated in affected tissue from AD brains 
and evidence suggests it may play a role in BACE1 regulation. In cancer, there is 
evidence that miR-9 can upregulate oncogenic pathways including proliferation, 
metastasis, and invasion. MiR-9 promotes stemness and prevents differentiation 
in glioma, increases cell motility and metastasis in CRC, promotes proliferation 
and or metastasis in breast, endometrial and cervical cancer, and is involved in 
translational regulation and inflammation pathways in HL.  
The evidence suggests that miR-9 may be important in AD, as it has been 
shown to be differentially expressed in cerebral regions which are significantly 
associated with pathological progression, yet more research is needed to clarify 
the molecular causative functions. Cancer research suggests a wide variety of 
possible functions that could be tested for parallel associations in AD, from 
transcriptional regulation, proliferation, inflammation, and high-impact 
translational regulation, to differentiation. Of note, miR-9 appears to have 
opposite influence on differentiation in neuronal development and glioma. If miR-
9 does upregulate differentiation, as suggested by the study of neuronal 
development, we might expect this miRNA to be upregulated in AD, resulting in a 
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decrease in neuronal precursors, and gradual neurodegeneration as a 
consequence of reduced neuronal renewal. This is supported by the reports of 
miR-9 upregulation in the brains of AD patients. 
C. MiR-29 
The majority of evidence suggests that miR-29 is downregulated in AD, 
though, similar to miR-9, there is some conflicting evidence regarding expression 
pattern. MiR-29 was inversely correlated with the density of amyloid plaques in 
adjacent tissue in brains from individuals with AD [244]. MiR-29b was also 
observed to be downregulated in the parietal lobe cortex of individuals with AD 
compared to age-matched controls [245]. Additionally, loss of miR-29a/b in 
sporadic AD was correlated with increased BACE1 expression, supporting 
downregulation of miR-29 in AD and also providing evidence that miR-29 may be 
directly involved in the amyloid pathway [228]. By contrast, in another study miR-
29a/b expression was increased in the medial frontal gyrus in AD patients [227]. 
This finding may reflect region-specific tissue expression; however, it is also 
important to consider methodological differences in this case. While the three 
papers documenting down-regulation of this miRNA utilized in situ hybridization 
by microarrays to measure expression, Cogswell et al. (2008) used real-time 
PCR. This method could introduce additional bias, since it requires primer 
amplification instead of direct measurement; therefore the consensus of the three 
other papers on miR-29a/b downregulation may be more credible in this 
instance.  
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MiR-29 also has been shown to inhibit neuronal apoptosis during 
development via inhibition of genes in the pro-apoptotic BH3-only family, which 
would otherwise inhibit pro-survival proteins in the BCL-2 family [246]. If one of 
the primary functions of miR-29 is inhibition of apoptosis, one might expect to 
observe downregulation in AD associated with an increased rate of 
neurodegeneration caused by members of the pro-apoptotic BH3-only family 
inhibiting expression of the BCL-2 family. For the majority of studies just 
mentioned, miR-29 was in fact downregulated in association with disease 
pathology as predicted by this hypothesis. Most current evidence suggests that 
miR-29 downregulation is associated with AD pathology. The upregulation 
observed by Cogswell et al. (2008) may reflect measurement in the medial frontal 
gyrus, a region which was not included in other studies.  
In cancer, miR-29 appears to interact directly with the BCL-2 family pro-
survival proteins. It was downregulated in malignant cholangiocarcinoma cells 
with corresponding upregulation of anti-apoptotic Myeloid cell leukemia sequence 
1 (MCL1, a member of the BCL-2 anti-apoptotic family). Transfection of miR-29 
decreased MCL1 expression and increased sensitivity to drug-induced 
cytotoxicity [247]. Supporting the validity of these results and suggesting that this 
function may be common in cancer, miR-29 was observed to be downregulated 
in melanoma, mantle cell lymphoma, acute myelogenous leukemia (AML), 
hepatocellular carcinoma (HCC), cervical cancer, endometrial serous 
adenocarcinoma, and non-small cell lung cancer (NSCLC), and transfection of 
miR-29 was correlated with decreased tumorigenicity [248-254]. In AML, miR-29 
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expression is negatively correlated with MCL1 mRNA, while in HCC BCL2 and 
MCL1 were both direct targets of miR-29; both of these findings support the 
theory that miR-29 functions as a tumor suppressor in cancer by promoting 
apoptosis [249,253]. 
In addition to this apoptotic pathway, previous cancer research also contains 
information linking miR-29 to other pathways. In mantle cell lymphoma, miR-29 
was shown to regulate Cyclin-dependent kinase 6 (CDK6) mRNA to influence 
cell division; downregulation of miR-29 was correlated with increased CDK6 and 
decreased survival [254]. This is supported by research in cervical cancer, which 
indicated that miR-29 level was negatively correlated with CDK6; addition of miR-
29 to human papillomavirus-infected cells was shown to retard cell cycle 
progression and increase the frequency of apoptosis [251]. In 
cholangiocarcinoma cells miR-29 was transcriptionally repressed by NF-kappaB 
protein, a key molecule in the inflammatory pathway, as well as c-Myc and 
hedgehog proteins, implicating this miRNA in proliferation downregulation 
[247,255]. In HCC, miR-29 was found to downregulate Matrix metalloproteinase-
2 (MMP2), leading to anti-angiogenesis via subsequent suppression of Kinase 
insert domain receptor (KDR, also called VEGFR2) signaling, as well as anti-
invasion effects [256]. Supporting this, in CRC, Apolipoprotein B mRNA editing 
enzyme catalytic polypeptide-like 3G (APOBEC3G) promotes metastasis via 
inhibition of miR-29 and subsequent upregulation of MMP2 [257]. In HCC miR-29 
was also implicated in upregulation of the long non-coding RNA Maternally 
expressed gene 3 (MEG3), accompanied by inhibited anchorage-dependent and 
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-independent cell growth and increased apoptosis [258]. Finally, miR-29 has 
been associated with transcriptional regulation in cancer via regulation of DNA 
methylation genes. In melanoma, miR-29 expression was inversely correlated 
with protein levels of DNA methyltransferases DNMT3A and DNMT3B, which 
affected overall survival [252]; miR-29 expression was also negatively correlated 
with DNMT3A and B in lung cancer, and transfection of miR-29 restored normal 
methylation patterns and expression of various tumor suppressor genes, as well 
as inhibiting tumorigenicity in vitro and in vivo [248]. From this evidence, miR-29 
appears to act as a tumor suppressor within a large variety of pathways involved 
in cancer including apoptosis, tumorigenicity, cell cycle regulation, proliferation, 
invasion, metastasis, angiogenesis, inflammation, and transcriptional regulation.            
This analysis of miR-29 implicates involvement in a variety of pathways in 
cancer, only one of which has been observed in AD. In addition to its activity in 
the amyloid pathway in AD, downregulation of miR-29 may allow BH3-only family 
proteins to inhibit BCL-2 family proteins, leading to apoptosis, while in cancer 
action of BH3-only family proteins must be blocked somehow, allowing BCL-2 
family proteins to promote survival since miR-29 is also downregulated. The 
additional interactions of miR-29 in cancer should also be investigated in AD; for 
example, NF-kappaB, which is known to be upregulated in AD, was shown to 
target miR-29 in cholangiocarcinoma, but to date has not been shown to target 
this miRNA in AD [259]. Given the findings in cancer, it would be useful to 
determine whether miR-29 regulates DNA methyltransferases in the brain, and, if 
so, whether these interactions influence AD pathology. 
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D. MiR-101 
Previous studies have demonstrated downregulation of miR-101 in the 
temporal and parietal cortex [228,245]. Subsequently, miR-101 was shown to 
downregulate APP; additionally, lentiviral-mediated overexpression of miR-101 
was observed to reduce fibrillar Aβ and another known target, Cytochrome c 
oxidase subunit II (COX2), in hippocampal neurons [260]. Another study 
replicated miR-101 downregulation of APP, and also demonstrated that miR-101 
is highly expressed in neural cells compared to HeLa and neuroblastoma cells 
[261]. These studies indicate that miR-101 downregulation results in increased 
Aβ and COX2, which has previously been shown to induce the innate immune 
complement component C1qB, and has been associated with inflammation 
[262,263]. Further, COX2 is elevated in hippocampal tissue in AD cases, and is 
correlated with amyloid plaque density [264]. MiR-101 therefore may play an 
important regulatory role in the amyloid, inflammatory, and immune pathways, 
and downregulation may exacerbate disease pathology.     
There is an extensive body of research on the multiple roles of miR-101 in 
cancer. MiR-101 is consistently downregulated in many cancers including acute 
lymphoblastic leukemia, HCC, glioblastoma, lung, gastric, colon, renal, prostate, 
ovarian, bladder, and pancreatic cancer [242,265-273]. Downregulation was 
associated with many oncogenic characteristics including increased proliferation, 
invasion, advanced tumor stage, and decreased survival; cellular transfection 
with miR-101 resulted in increased apoptosis and inhibited proliferation, invasion, 
and angiogenesis, via inhibition of expression of primary target molecules such 
135 
 
as the histone methyltransferase Enhancer of zeste homolog 2 (EZH2), COX2, 
and MCL1. EZH2 is a transcriptional regulatory molecule which can potentially 
regulate many different pathways, greatly increasing the impact of miR-101 
activity or loss. Redundancy is reflected in miR-29 and miR-101 regulation of the 
anti-apoptotic MCL1, indicating that this is an important pathway in cancer and 
highlighting the potential for future AD research, given that molecules involved in 
cell survival could play an important role in neurodegeneration. As discussed 
earlier, COX2 has been implicated in inflammatory and immune pathways; this 
functional interaction is seen in both AD and cancer, reflecting the importance of 
these pathways in both diseases and indicating that miR-101 may be a key 
negative regulator of both diseases.   
E. MiR-107 
MiR-107 downregulation has been reported in AD and has been related to 
amyloid plaque density, neuritic plaque counts, and neurofibrillary tangle counts 
in adjacent tissue [244,274]. Additionally, miR-107 has been correlated with 
BACE1 mRNA level, and BACE1 has been shown to have miR-107 sequence 
target sites. Thus in AD, miR-107 may be a regulator of BACE1 activity and 
consequently affect APP cleavage [274,275]. These results support the role of 
miR-107 downregulation in AD and suggest a mechanism related to plaque 
burden. 
Regulation in cancer is more of a mixed picture; there is conflicting evidence 
for miR-107 regulation in prostate cancer and gastric cancer, indicating that more 
research on this topic is needed. In prostate cancer, there is evidence that 
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downregulation of miR-107 is correlated with upregulation of the mitogen and 
growth factor Granulin (GRN); other members of this miRNA family have also 
been shown to display this pattern of downregulation with associated 
upregulation of GRN in 11 different types of cancer [276]. In contrast, a 
significantly higher level of miR-107 was found in the urine of men with prostate 
cancer, suggesting that this miRNA may be upregulated [277]. Additional 
research is needed to resolve this apparent discrepancy. In gastric cancer, there 
is also conflicting evidence for regulation of miR-107; expression was 
significantly elevated in gastric tumor tissue compared to normal tissue, was 
associated with depth of invasion, lymph node metastasis, and stage, decreased 
overall survival and disease-free survival, and was inversely correlated with 
DICER1 mRNA, indicating possible involvement in translational regulation 
[234,278]. However, miR-107 was also observed to be silenced in gastric cancer 
cells, and transfection of miR-107 was correlated with downregulation of CDK6 
mRNA and reduced protein expression, cell cycle arrest, and decreased 
proliferation and invasion [279]. At this time, more research is needed to clarify 
the roles of miR-107 in prostate and gastric cancer, and whether it is ultimately 
oncogenic or tumor suppressive. 
MiR-107 has also been shown to be upregulated in breast cancer, and 
downregulated or silenced in HNSCC, colon cancer, and pancreatic cancer. In 
breast cancer, miR-107 was found to be upregulated, was shown to silence the 
tumor suppressive miRNA let-7, and was associated with increased tumorigenic 
potential and metastases in mice [188]. In HNSCC, low expression of miR-107 
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was correlated with increased Protein Kinase Cδ (PKCδ), and miR-107 inhibited 
proliferation, DNA replication, colony formation, and invasion [280]. MiR-107 has 
been implicated in angiogenesis in colon cancer; the tumor suppressive 
transcription factor p53 can mediate transcription of miR-107, and forced 
expression of miR-107 suppresses expression of Hypoxia inducible factor-1beta 
(HIF1b), suppressing angiogenesis, tumor growth, and Vascular endothelial 
growth factor (VEGF) expression [281]. Finally, in pancreatic cancer cell lines, 
miR-107 was reported to be epigenetically silenced, and re-expression by a 
demethylating agent in tumor cell lines inhibited CDK6 and decreased growth in 
vitro, indicating that miR-107 is also involved in a cell cycle regulatory pathway 
[282]. It is possible that the regulation of let-7 by miR-107 in breast cancer 
overrides other interactions since let-7 has been shown to affect a large number 
of targets, and that this level of regulation may be blocked in other cancers, 
allowing other miR-107 interactions to take precedence and produce tumor 
suppressive effects.   
A number of different pathways appear to be regulated by miR-107 in cancer 
including proliferation, invasion metastasis, cell cycle regulation, additive 
translational regulation (mediated by let-7), and angiogenesis. More information 
on the potential interaction of miR-107 with DICER1, CDK6, HIF1b, and GRN 
could further elucidate the molecular pathways involved in AD, as well as the 
regulatory process of disease initiation and progression. GRN is a particularly 
interesting association, given that it has been found to cause one form of 
frontotemporal lobar degeneration [283]. The altered expression patterns for 
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various types of cancer and AD may indicate that there is another level of 
regulation that differs across tissues. This in turn may be modulated by other 
miRNAs, which could alter the methylation status of miR-107 via interaction with 
histone methyltransferases.    
F. MiR-125b 
Small increases in miR-125b have been observed in the hippocampal region 
of AD brains post-mortem. Because synapsin II mRNA has been identified as a 
target for this miRNA, it has been postulated that it may be responsible for 
synapsin protein deficits observed in the brains of patients with AD [219,229,284-
287]. MiR-125b has been shown to be significantly upregulated in the temporal 
lobe neocortex of AD patients [220,221]. MiR-125b was also found to be 
upregulated in the hippocampus, medial frontal gyrus, and cerebellum [227]. 
Further, miR-125b was positively correlated with gray matter neurofibrillary 
tangles in post-mortem AD patients [244]. Finally, in cultured human neuronal-
glial cells, miR-125b has been shown to be upregulated by NF-kappaB in 
response to IL-1β and Aβ42-peptide-induced stress; in this model, miR-125b was 
also shown to target the mRNA of Complement factor-H (CFH), known to be an 
important suppressor of immune and inflammatory pathways in the brain, and 
lead to decreased expression [259,288]. From these reports, miR-125b is 
implicated in neuropathological change, and appears to function in the 
inflammatory and oxidative stress NF-kappaB pathways, innate immunity via 
CFH, and cellular transport via synapsin. 
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In cancer, miR-125b appears to function mostly as a tumor suppressor. The 
majority of research to date has been done in HCC; downregulation of miR-125b 
has been linked to tumor progression and metastasis, tumorigenicity, 
proliferation, migration, invasion, angiogenesis, and cell cycle de-regulation in 
HCC or HCC cell lines [289-291]. In this disease, miR-125b was shown to be 
silenced by methylation; miR-125b was also shown to decrease angiogenesis via 
regulation of Placenta growth factor (PIGF), a member of the VEGF family, as 
well as MMP2 and MMP9, which may be involved in miR-125b effects on 
invasion [289]. Investigation of the effects of miR-125b on angiogenesis in more 
depth in epithelial cells reveal contradictory evidence that VEGF can induce miR-
125b, which in turn inhibits translation of Vascular endothelial cadherin (VE-
cadherin) and in vitro tube formation; overexpression of miR-125b was shown to 
result in nonfunctional blood vessel formation, indicating that miR-125b could 
promote angiogenesis [292]. It is possible that this contradiction is caused by the 
model; miR-125b may act through different pathways in cancerous tissue.  MiR-
125b was also shown to upregulate Cyclin dependent kinase inhibitor 1 
(CDKN1A) expression, which arrested cell cycle transition and silenced Lin-28 
homolog B; these effects were linked to inhibited growth, migration, and invasion 
(Liang et al., 2010). The histone methyltransferase EZH2 was shown to 
downregulate miR-125b in HCC, resulting in progression and metastasis [290]. In 
bladder cancer, miR-125b also appears to function as a tumor suppressor; miR-
125b inhibits E2F transcription factor 3 (E2F3), which is involved in the G1/S 
phase cell transition, and transfection of miR-125b in bladder cancer cell lines 
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decreased E2F3 protein and Cyclin A2, depressing colony formation in vitro and 
tumor development in mice [293]. Contrary to these results, a study in glioma 
found that miR-125b promotes glioma cell proliferation and inhibits drug-induced 
apoptosis, indicating that it may play an oncogenic role in this particular disease; 
the authors further found that miR-125b may target and downregulate apoptosis-
related protein BCL-2 modifying factor, and apoptotic activator (BMF) [294]. 
Aside from glioma, miR-125b seems to play a tumor suppressive role in a variety 
of molecular pathways, though miR-125b should be investigated to determine 
whether this is also true in other cancer types.   
Given the largely tumor suppressive function of miR-125b, which inhibits 
growth and is downregulated in cancer, we would expect miR-125b to be 
upregulated in AD with resulting neurodegeneration, which has been observed 
as noted above. However, the specific interactions of miR-125b with molecules in 
a large variety of pathways have not been investigated in AD; research to 
determine whether miR-125b directly interacts with the molecules genes above 
including angiogenic VEGF, cell cycle regulatory E2F3, and apoptotic activator 
BMF could shed more light on the molecular mechanisms involved in AD 
pathology and further elucidate the pathways involved in this disease. 
Interestingly, the role of miR-125b in innate immunity does not appear to have 
been specifically investigated in cancer at this point; this could be an important 
factor in cancer etiology which should be further investigated as well. 
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G. MiR-146 
Similarly to miR-125b, miR-146a was found to be significantly upregulated in 
the temporal cortices of patients with AD [220,221]. It was shown to function 
similarly to miR-125b in the AD inflammatory and oxidative stress pathways, as it 
was shown to be upregulated by NF-kappaB in response to IL-1β and Aβ42 or 
oxidative stress in cultured human neuronal-glial cells, and to decrease 
expression of CFH [259,288,295]. Consistent with these results, miR-146a was 
observed to be upregulated in AD neocortices, and in IL-1β and Aβ42 stressed 
human astroglial cells; in the astroglial model miR-146a downregulates the Toll-
like receptor signaling molecule Interleukin (IL)-1 receptor-associated kinase 1 
(IRAK1) in tandem with IRAK2 upregulation by NF-kappaB to promote the innate 
immune and inflammatory responses [295]. Interestingly, unlike miR-146a, miR-
146b was downregulated in both the hippocampus and medial frontal gyrus in 
individuals with AD; the researchers postulate that downregulation of miR-146b 
relieves inhibition of IRAK1 and another toll-like receptor signaling molecule, TNF 
receptor-associated factor 6 (TRAF6), triggering the innate immunity pathway 
which contributes to the activation of microglia and neurodegeneration [227]. 
More work is needed to clarify these apparently contradictory roles of miR-146a/b 
in AD. 
Upregulation of miR-146a was observed in anaplastic thyroid carcinoma 
(ATC) and cervical cancer, while downregulation was observed for miR-146a in 
pancreatic cancer, and miR-146a and b in prostate and breast cancer, indicating 
that these miRNAs may play a variety of oncogenic or tumor suppressive roles in 
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different cancers [296-302]. MiR-146a has been characterized as oncogenic in 
anaplastic thyroid carcinoma, activated by the inflammatory molecule NF-
kappaB; inhibition of miR-146a decreased oncogenic potential in ATC-derived 
cells and increased susceptibility to chemotherapy-induced cytotoxicity [301]. 
Additional oncogenic function was observed in cervical cancer, wherein miR-
146a was significantly upregulated in cervical cancer and was tied to cellular 
proliferation [302]. In contrast, miR-146a and b have also been shown to have a 
variety of tumor suppressive functions in breast, prostate, and pancreatic cancer. 
Functional interaction research in breast cancer indicates that Breast cancer 
metastasis suppressor 1 (BRMS1) upregulates miR-146a and b; expression of 
either miRNA resulted in downregulation of Epidermal growth factor receptor 
(EGFR) and reduced invasion, migration, and metastasis [297].  
Also in breast cancer, miR-146a and miR-146b expression suppressed 
IRAK1 and TRAF6, which was reported to impair NF-kappaB activity, resulting in 
reduced invasion and migration [296]. This negative feedback loop was also 
observed previously in an acute monocytic leukemia cell line, indicating that miR-
146a and b appear to be involved in negatively as well as positively regulating 
oxidative, immune, and inflammatory responses [303]. Transfection of miR-146a 
in prostate cancer cell lines led to significantly reduced expression of Rho-
associated, coiled-coil containing protein kinase 1, and reduced proliferation, 
invasion, and metastasis; downregulation of either miR-146a or b in prostate 
cancer was also linked to focal basal cell layer disruptions, which have been 
correlated with invasion [299,300]. Similarly, re-expression of miR-146a induced 
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by isoflavone in pancreatic cancer was also correlated with reduced invasion and 
downregulation of IRAK1 and EGFR, indicating that this molecular pathway is 
involved in multiple cancers [298]. Finally, genetic studies have linked 
polymorphisms in miR-146a to increased risk of gastric cancer, breast cancer, 
and papillary thyroid carcinoma, while meta-analyses have also linked risk to 
more generalized cancer susceptibility [304-308]. These various disparate pieces 
of evidence indicate that miR-146a plays a variety of roles in different cancer 
types, though there seems to be a commonality to the interactions observed for 
the tumor suppressive roles miR-146a plays in prostate, pancreatic, and breast 
cancer. More research would be helpful in clarifying the mediatory mechanisms 
which determine whether miR-146a is tumor suppressive or oncogenic. 
Comparing the evidence for miR-146a function in AD and cancer, there 
seems to be more overlap than for the miRNAs previously reviewed, though 
results from cancer may still inform additional interactions in AD. For instance, an 
investigation of miR-146a regulation of EGFR in AD may tie this miRNA to a 
proliferative pathway; logically, if these molecules are negatively regulated and 
miR-146a is upregulated in AD, one would expect a decrease in EGFR, with 
possible subsequent neurodegenerative effects. For example, in rodents with 
traumatic brain injury, treatment with epidermal growth factor reduced 
hippocampal neuronal cell loss and improved cognitive function [309]. 
Interestingly, modulation of the inflammatory/innate immune pathway by miR-
146a appears to be play a large role common to both diseases. The evidence 
that miR-146a and b inhibit IRAK1 and TRAF6 in breast cancer may contradict 
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the hypothesis of Cogswell et al. (2008) that miR-146b relieves inhibition of these 
molecules in AD, though a functional study of this interaction, as well as the 
subsequent NF-kappaB modulation, would be required for clarification. Finally, it 
is important that future studies make an effort to clarify the role of miR-146b in 
cancer, as many results to date have concerned miR-146a; since there seems to 
be functional overlap based on current research, it would be interesting to 
investigate further whether these two miRNAs may be differentially regulated in 
AD. 
H. MiR-153 
This miRNA has not been studied as extensively as others mentioned in this 
review, but is discussed because it has been very recently implicated in 
regulation of APP. Long and colleagues found that delivery of miR-153 in human 
fetal brain cultures reduced expression of APP, as well as an APP paralogue, 
Amyloid beta (A4) precursor-like protein 2, via direct interaction with a target site 
on the APP 3’ UTR, while inhibition of miR-153 resulted in increased expression 
of APP; supporting this, decreased miR-153 and increased APP were observed 
in a subset of AD patients with moderate pathology [310]. Given this important 
functional evidence for miR-153 interaction in the amyloid pathway, it seems 
important to review current research of this miRNA in cancer to see if we can 
extrapolate any further roles or further elucidate molecular function for miR-153. 
As with the results for AD, a review of cancer research does not yield much 
information on miR-153; however, the few studies published may shed additional 
light of the function of this regulatory molecule. In ovarian cancer, miR-153 was 
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downregulated, and expression was different for four histopathological types of 
ovarian cancer; the researchers subsequently found that miR-153 was 
significantly correlated with tumor grade and clinical stage [311]. A key study 
found that miR-153 is downregulated in glioblastoma, with re-expression in cell 
lines associated with decreased proliferation and increased apoptosis; the 
researchers further demonstrated that miR-153 directly inhibited anti-apoptosis 
molecules BCL2 and MCL1 [312]. An additional study in the same model found 
that miR-153 also inhibits the insulin receptor substrate 2 (IRS2), further 
implicating it in growth regulation [313]. These studies characterize the tumor 
suppressive role of miR-153, as well as specific interactions which appear to 
mediate this function. Interestingly, the same endometrial cancer study 
mentioned previously for miR-9 also found that miR-153 has similar oncogenic 
properties, appearing to downregulate FOXO1 and apoptosis [243]. This 
oncogenic function seems to contradict other tumor suppressive functions listed 
above and indicates that this miRNA would benefit from more intense scrutiny. 
Mediation of BCL2 and MCL1 by miR-153 indicates that it may have 
overlapping functionality with miR-29 and 101; however, the majority of evidence 
indicates that these miRNAs are downregulated in AD, whereas if they were 
inhibiting anti-apoptotic molecules, we would expect them to be upregulated in 
AD leading to neurodegeneration. Additional research is needed to determine if 
miR-153 can also inhibit anti-apoptosis molecules in the brain, as well as why 
this interaction would be suppressed in a neurodegenerative disease like AD. 
Interestingly, if miR-153 does in fact interact with IRS2, that would tie this miRNA 
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to the insulin regulatory pathway; in addition to the known association of diabetes 
with increased dementia risk, there is some evidence that insulin may be directly 
involved in AD, so this association should be a focus of further investigation [314-
317]. 
I. MiR-195 
There is comparatively little evidence for the involvement of miR-195 in AD; 
however, miR-195 has been shown to directly target the 3’ UTR of BACE1, and 
to decrease protein expression in mouse neuroblastoma cells, with a 
corresponding drop in Aβ levels [318]. Additionally, miR-195 was decreased in 
the cerebrospinal fluid (CSF) of AD patients compared with controls [227], while 
another group found that miR-195 was downregulated and was negatively 
correlated with diffuse amyloid plaques in the gray matter of post-mortem AD 
patients [244]. Given these limited but interesting results, it seems important to 
review the roles of miR-195 in cancer to see if additional information about miR-
195 in the brain can be extrapolated for further investigation. Since 
downregulation could theoretically be tied to increased amyloid beta levels, 
establishing expression patterns of this miRNA in AD brain tissue should be a 
research priority, along with more functional investigation.   
Importantly, miR-195 has been extensively studied in cancer, with current 
research indicating that it plays tumor suppressive or oncogenic roles in different 
cancer types. Downregulation was observed in a number of different cancer 
types, and was associated with poorer overall survival, increased metastasis 
incidence, and higher tumor stage; however, upregulation was also observed in 
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several cancer types [319-330]. In breast cancer and glioma, conflicting studies 
indicate that more research is needed to determine the impact of this miRNA 
[331-335]. Research in the tumor suppressive functions of miR-195 has shown 
that it interacts with a number of molecules involved in cell cycle regulation, as 
well as metabolic and anti-apoptotic molecules. MiR-195 was shown to inhibit 
Cyclin D1 in HCC and breast cancer [328,334], Cyclin D3 in glioblastoma [330], 
Cyclin dependent kinase 4 in bladder cancer [322], CDK6 in HCC [328], E2F3 in 
HCC and glioblastoma [328,330], BCL2 in breast and colorectal cancer 
[323,336], Raf-1 proto-oncogene, serine/threonine kinase in breast cancer [334], 
and Glucose transporter type 3 (GLUT3) in bladder cancer [337]. The role of 
miR-195 in suppression of anti-apoptotic BCL2 lends support to the evidence that 
miR-195 is downregulated in breast cancer, promoting cell survival. 
Unsurprisingly given these genes’ known roles in cell cycle regulation, 
metabolism, and anti-apoptosis, inhibition via miR-195 was variously associated 
with cell cycle arrest, decreased proliferation, reduced invasion, increased 
apoptosis, and reduced colony formation and tumor formation. Interestingly, 
given that the only clinical measure associated with upregulation at this point is 
increased resistance to Temozolomide [335], it is possible that the tumor 
suppressive functions of miR-195 early in cancer development are overridden by 
oncogenic interactions favoring survival in the context of drug resistance; further 
investigation of this is merited in cancers associated with miR-195 upregulation 
as listed above. The dearth of functional and clinical investigation of miR-195 
upregulation, as well as the contradiction between research indicating that it may 
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be up or downregulated in breast cancer and glioblastoma, should be addressed 
to further clarify the mechanisms of miR-195 in cancer.   
From the current literature detailing the tumor suppressive role of miR-195 in 
various cancers, it is possible to hypothesize that this miRNA has functional 
overlap with miR-29 and miR-153, both of which have been shown to interact 
with BCL2, which would lead to the additional hypothesis that miR-195 is 
similarly downregulated in AD. This is a logical expectation given the functional 
evidence that decreases in miR-195 could be tied to increased amyloid beta and 
decreased levels were observed in CSF and gray matter, however, it requires 
further investigation. Researching these premises might also point to the 
possibility that all three miRNAs are regulated via a common mechanism in AD 
given their apparent redundancy. As suggested earlier, further investigation in 
AD of the functional interactions ascribed to this miRNA in cancer might help 
elucidate additional mechanisms by which it influences AD pathology. Given the 
evidence in cancer, it is possible that this miRNA is also important in proliferative 
pathways in the brain.  
J. Pathways 
The overall involvement of miRNAs under consideration in this review in 
specific biological pathways is summarized in Figure 19, including oncogenic and 
tumor suppressive functions in cancer and amyloid-specific mechanisms. The 
amyloid pathway has clearly been a focus of AD research to date. We have 
reviewed evidence that multiple miRNAs regulate expression of molecules in this 
pathway; miR9, 29a/b, 107, and 195 have been predicted or shown to target, or 
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negatively correlated with, BACE1 mRNA or protein levels, suggesting that these 
miRNAs may have functional overlap or redundancy, while miR-101 and 153 
have been shown to inhibit APP protein directly (Figure 17). 
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Figure 19. Summary of MiRNA Pathway Relationships in Cancer and AD. 
Major pathways are listed; dots indicate evidence that a specific miRNA is 
involved in a particular pathway. Red indicates evidence from cancer research, 
blue from AD research, and purple from both cancer and AD. 
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In addition, miR-9, 125b, and 146a are upregulated by the inflammatory and 
oxidative stress responses, suggesting that the amyloid pathway may have wide-
reaching regulatory impact via miRNA. 
The inflammatory and innate immune pathways have been extensively 
investigated in both cancer and AD. MiRNAs appear to be important in these 
pathways in both diseases and may function using some of the same 
mechanisms (Figure 20). Regulation involving the major inflammatory and 
oxidative stress transcription factor NF-kappaB is a common theme observed for 
many of the miRNAs reviewed here. This molecule is a key signaling molecule in 
AD as it appears to tie together the amyloid, inflammatory, oxidative stress, and 
innate immunity pathways, but it has also been shown to play an important role in 
cancer. As discussed earlier in this review, in cancer, miR-9 downregulates 
NFKB1 and NF-kappaB appears to directly downregulate miR-29a and 
upregulate miR-146a, while in AD, NF-kappaB appears to upregulate miR-9, 
miR-125b, and miR-146a. MiR-125b and 146a regulate several other molecules 
in the NF-kappaB pathway and indirectly modulate NF-kappaB; miR-146a has 
been shown to downregulate Toll-like receptor signaling molecules IRAK1 and 
TRAF6 in cancer, with a corresponding drop in NF-kappaB level. Interestingly, 
miR-146a was also shown to downregulate IRAK1 in AD, but did not affect 
TRAF6 in the Aβ42 and IL-1β-stressed human cultured astroglial cell model 
[295]. This process has been postulated to result in ‘fine-tuning’ of these 
pathways, and may be aided by miR-9 downregulation of NFKB1, though this 
remains to be verified in AD. Given the similar expression and activation of miR-
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125b compared with miR-146a, it would also be interesting to investigate whether 
this miRNA may also regulate downstream toll-like receptor signaling via a 
similar mechanism.   
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Figure 20. MicroRNA Involvement in the Inflammation, Innate Immunity, and 
Oxidative Stress Pathways in AD and Cancer. This pathway has been 
validated by several studies in AD; however, additional evidence from cancer 
research points to more molecules which may be involved. Blue lines indicate 
interactions and effects found in AD research, orange lines indicate interactions 
and effects found in cancer research, and black lines indicate findings common 
to both diseases. Dashed lines indicate downstream effects. 
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Additionally, in AD, miR-125b and 146a have been shown to regulate CFH, 
which normally represses the cerebral inflammation response. CFH has also 
been shown to play an important regulatory role in the complement cascade, 
which is a major component of innate immunity. Dysregulation has also been 
observed in Down syndrome, which shares some neuropathological 
characteristics of AD [338]. Interestingly, CFH polymorphisms have been 
previously associated with increased risk of AD in Apolipoprotein E ε4 carriers, 
indicating that this miRNA regulatory mechanism could be an important factor in 
pathology, and should be further investigated [339]. Based on the evidence in 
cancer research, an investigation of the interaction of miR-9 and 29b with NF-
kappaB in AD and possible downstream targets in these pathways may further 
clarify the molecular mechanisms involved. MiR-101 regulation of COX2, which 
has been associated with innate immunity and inflammation, adds complexity to 
this regulatory pathway. We conclude that the innate immune, oxidative stress, 
and inflammatory pathways regulated by miRNAs are important in cancer and 
AD, and utilize some overlapping functional mechanisms; further research into 
each area based on previous research presented here could help to advance 
knowledge in both disease areas. 
To date, most miRNA research on functional molecular interactions in AD has 
focused on the amyloid and inflammation pathways since these have been 
directly implicated in neuropathology. However, a number of other pathways 
have been postulated or demonstrated to play a role in AD including proliferation 
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and angiogenesis. Metastasis and invasion, key topics in cancer research, have 
been shown to be effectively regulated by miRNAs.  
Given that some of the underlying functions of extracellular matrix 
degradation, stemness, and differentiation could affect neurophysiology and be 
involved in AD, miRNAs regulation of matrix metalloproteinases, cyclin-
dependent kinases, and cyclins, all of which have been observed in cancer, 
should also be investigated in AD. Proliferative molecules including GLUT3 and 
IRS2, which are specifically involved in cell metabolism and appear to be 
differentially regulated by miRNAs in cancer, could also contribute to risk for AD 
and increased rates of neurodegeneration via impaired metabolism. Pro-survival 
genes such as BCL2 and MCL1 have been observed to be redundantly regulated 
by multiple miRNAs in cancer; inappropriate silencing of these molecules by 
miRNAs in AD could exacerbate neurodegeneration. Cell cycle regulatory 
molecules such as cyclin-dependent kinases, cyclins, and E2F3, are shown to be 
targets of several of the miRNAs discussed, indicating that these miRNAs can 
inhibit the cell cycle (Figure 21).  
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Figure 21. Redundant MicroRNA Mechanisms Regulating Proliferation and 
Survival Pathways in Cancer. Expression of transcription factors, BCL-2 family 
genes and inhibitors, and cell cycle regulatory molecules is redundantly regulated 
by miRNAs in cancer, prompting speculation about possible regulatory roles of 
these miRNAs in a similar pathway in AD. 
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Amyloid beta appears to upregulate angiogenesis, suggesting that this may 
be an important area for future miRNAs research in AD [340]. As discussed 
earlier, various miRNAs have been shown to play important roles in angiogenesis 
in cancer. MiR-29 downregulates MMP2, indirectly reducing VEGFR2 signaling 
and angiogenesis, miR-107 reduces HIF1b, with subsequently reduced 
angiogenesis, tumor growth, and VEGF expression, and miR-125b was shown to 
inhibit PIGF and VE-cadherin in different cell lines, inhibiting angiogenesis. 
Interestingly, all instances of angiogenic regulation observed here were tumor 
suppressive, indicating a degree of functional redundancy, but one of the four 
miRNAs implicated was upregulated in AD. MiR-125b may be differentially 
expressed because it has been shown to be upregulated by amyloid beta. 
TRAF6, the innate immune molecule downregulated by miR-146a in breast 
cancer, has also been shown to negatively regulate VEGF in epithelial cells, 
leading to the question of whether the miR-146a regulatory pathway may result in 
increased VEGF signaling and angiogenesis [341]. This pathway, which has 
been implicated in AD, should be further investigated for miRNA regulation to 
elucidate function and disease risk factors.       
Transcriptional and translational regulation of miRNAs and target genes is 
also a key process in both diseases, with multiple hierarchical levels of control 
and feedback mechanisms playing important roles in effect size and specificity. 
While miRNAs are inherently involved in translational regulation via the RISC 
silencing complex (Figure 16), several miRNAs in this review have may affect 
translational regulation at a higher level; both miR-9 and 107 have been shown to 
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inhibit DICER1, and miR-107 has been shown to inhibit another miRNA, let-7. 
Interestingly, miR-29 and 101 have been implicated in transcription control via 
inhibition of methyltransferases. An investigation of these properties could 
elucidate additional functions of these miRNAs and provide information on this 
important regulatory pathway in AD. 
K. Conclusions 
MiRNAs are clearly a relevant topic for both cancer and neurodegenerative 
disease. Many of the miRNAs discussed in this review have differential 
expression in AD and cancer, suggesting that they play multiple regulatory roles 
in pathways active across both cancer and AD (Table 20). While miRNA has 
been actively researched in cancer for a number of years, this is a relatively new 
area for research in AD and other neurodegenerative diseases. From a review of 
the literature on miRNAs in AD, much work remains to be accomplished to 
elucidate all roles of miRNAs in pathological pathways. Reviewing a number of 
miRNAs with functional evidence of involvement in AD indicates that other than 
the amyloid pathway and inflammation, possible regulation of other pathways by 
these molecules has been largely ignored. This review of miRNA regulatory 
mechanisms in cancer and AD has covered a variety of important molecular 
mechanisms observed in cancer that could potentially also contribute to 
pathology in AD. Further investigation of these pathways and mechanisms 
appears warranted and will hopefully be a focus of future research. Studies 
addressing other biological pathways such as proliferation and angiogenesis 
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would be important and help fill the gaps in our understanding of the regulatory 
mechanisms influencing this very complex disease.  
A comparison of research on miRNAs in cancer and AD highlighted areas 
which could benefit from future research in both diseases. Though the primary 
focus was on increasing knowledge of AD from previous research in cancer, this 
case study also demonstrates that a similar strategy could be useful in studying 
other neurodegenerative diseases, which are starting to experience increasing 
attention with regard to the roles of miRNAs in disease pathophysiology.  
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Table 20. MiRNA Expression in Cancer and AD. MiRNAs are significantly 
differentially expressed, indicating different roles in disease.   
 Types of Cancer (see text for citations) Alzheimer's disease affected tissue 
MiRNA Downregulated Upregulated Downregulated Upregulated 
miR-9 
Melanoma and 
HNSCC 
Glioma, GC, 
biliary, Hodgkin 
lymphoma, 
CRC, BC, 
cervical 
Hippocampus 
and medial 
frontal gyrus, 
and ATC 
Hippocampus, TL 
miR-29 
Cholangiocarcinoma, 
melanoma, MCL, 
AML, HCC, cervical, 
non-small cell lung 
  
SMTG, parietal 
lobe cortex, 
and ATC 
Medial frontal 
gyrus 
miR-101 
ALL, HCC, glioma, 
lung, GC, colon, renal, 
PC, ovarian, bladder, 
and pancreatic 
 
Parietal lobe 
cortex, and 
ATC 
 
miR-107 
GC, PC, HNSCC, 
colon, and pancreatic 
GC, PC, BC 
SMTG 
(replicated) 
  
miR-125b HCC, bladder glioma   
TL, hippocampus, 
medial frontal 
gyrus, and 
cerebellum, and 
HNG 
miR-146a 
anaplastic thyroid, 
cervical 
pancreatic, PC, 
BC 
  
TL, HNG, and 
human astroglial 
cells  
miR-153 ovarian, glioma endometrial Frontal cortex   
miR-195 
BC, glioma, CRC, 
bladder, 
adrenocortical, HCC, 
primary peritoneal 
BC, glioma, 
astrocytoma, 
CLL, malignant 
mesothelioma 
CSF, and 
SMTG 
  
HNSCC=head and neck squamous cell carcinoma, GC=gastric cancer, CRC=colorectal cancer, 
BC=breast cancer, ATC=anterior temporal cortex, TL=temporal lobe neocortex, MCL=mantle cell 
lymphoma, AML=acute myelogeneous leukemia, HCC=hepatocellular carcinoma, SMTG= 
Superior and middle temporal gyri, ALL=acute lymphoblastic leukemia, PC=prostate cancer, 
HNG=human neuronal-glial cells in culture, CLL=chronic lymphocytic leukemia 
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VII. Conclusions and Future Directions 
In this work we have identified several important directions for research on 
cancer and treatment-related cognitive dysfunction, and have taken the first 
steps towards addressing these questions. 
First, our review of neuroimaging studies of cancer and treatment-related 
cognitive dysfunction (Chapter II, Holohan et al. (2013)) suggested that additional 
multimodal longitudinal neuroimaging studies would aid in clarifying the course 
and duration of cognitive dysfunction, as well as potentially contributing to our 
knowledge of biological mechanisms driving this effect. To begin to address this 
question, we conducted a longitudinal, multimodal neuroimaging study of blood 
flow and gray matter density in breast cancer patients (Chapter III, Nudelman et 
al. (2014)). This work answered a question which had been raised by previous 
studies, which showed activation alterations (suggesting hyper- and 
hypoperfusion) [16], and others which showed frontal gray matter density 
decrease (suggesting hypoperfusion); our results showed a significant cluster of 
chemotherapy treatment-associated hyperperfusion in the precentral gyrus 
compared to health controls, but also showed other areas of hypoperfusion 
associated with frontal gray matter density decrease [17,119]. Importantly, these 
results support the hypothesis that multiple biological mechanisms may be 
driving chemotherapy treatment-associated cognitive dysfunction.  
To continue to examine the question of whether multiple biological 
mechanisms drive cancer and treatment-related cognitive dysfunction, we utilized 
other data collected in this breast cancer cohort on chemotherapy-induced 
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peripheral neuropathy symptoms (CIPN-sx). Again using a multimodal, 
longitudinal design examining blood flow and gray matter density, we were able 
to show that CIPN-sx were associated with increased blood flow in regions of the 
brain known to be associated with pain processing, and also to show that this 
result was positively correlated with the previously observed gray matter density 
decrease (Chapter IV, Nudelman et al. (under review)). This indicates that 
individuals who did not experience significant gray matter density decrease did 
show increased blood flow in regions associated with pain processing. Again, this 
supports the hypothesis that multiple mechanisms are driving cancer and 
treatment-related sequelae. 
To continue to address the question of mechanisms driving cancer and 
treatment-related cognitive dysfunction and other sequelae, it will be important to 
extend these findings beyond breast cancer. To begin to address this question, 
we analyzed gray matter density, comparing cancer survivors (CA+) and those 
who had not reported any cancer incidence (CA-) across diagnostic groups in the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort (Chapter V, 
Nudelman et al. (2014)), and were able to demonstrate lower frontal gray matter 
density in CA+, across diagnostic groups, in regions similar to those observed in 
other imaging studies of cancer and treatment-related cognitive dysfunction 
[15,17,342]. This finding is particularly interesting in light of the high prevalence 
of skin and prostate cancer in this cohort, as both of these cancer types are not 
typically treated with chemotherapy. Future research will be needed to clarify the 
driving mechanism behind this finding, by separately investigating gray matter 
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density in different types of cancer and accounting for treatment effects. 
However, these initial results do imply that other types of cancer aside from 
breast may also exhibit gray matter density alterations, suggesting that other 
findings from breast cancer studies may be more widely applicable to other types 
of cancer and highlighting the need for further study in this area. 
Interestingly, in the ADNI cohort study, cancer history was also shown to 
delay Alzheimer’s disease (AD) age of onset, suggesting that the mechanism 
driving the inverse association of cancer and AD may be independent of cancer 
and treatment-related cognitive dysfunction. This highlights the need for more 
investigation of other pathways potentially driving this inverse association.  
To further advance the understanding of potential mechanisms driving this 
effect, we have reviewed microRNAs (miRNAs) identified separately in studies of 
cancer and AD and analyzed potential overlap (Chapter VI, Holohan et al. 
(2012)), as we hypothesized that a greater understanding of the biological 
mechanisms driving the inverse association of cancer and AD would be 
informative towards the study of cognitive dysfunction as well. Our review 
highlights eight miRNAs with evidence of differential regulation in cancer and AD 
of a number of important biological pathways, including proliferation, survival, cell 
cycle regulation, tumor suppression, apoptosis, angiogenesis, inflammation, 
innate immunity, and AD-specific pathways such as amyloid-beta plaque 
deposition. Importantly, seven of the eight miRNAs reviewed were shown to be 
involved in AD-specific pathways, and were also separately shown to be involved 
in pathways promoting or inhibiting cancer. This supports the hypothesis that 
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differential expression or regulation of microRNAs may have wide-ranging 
impacts on a number of different disease pathways in cancer and AD, and that 
the same microRNAs may be influencing the risk and/or trajectory of both 
diseases. Additionally, studies of five of the eight miRNAs reviewed showed 
evidence of involvement in inflammatory and immune pathways in cancer and 
AD, supporting the hypothesis that common pathways might be differentially 
regulated to promote each disease.  
Our findings from the studies of cancer and cognitive dysfunction (Chapters 
II-V) highlight the importance of future study in this area. Our review (Chapter II, 
Holohan et al. (2013)) and the novel findings presented in Chapter III (Nudelman 
et al. (2014)), highlight the importance of continuing to apply the latest advances 
in neuroimaging methodologies to study of this research topic, as well as the 
need for more prospective, longitudinal, and multimodal analyses with 
appropriate controls, in order to integrate findings into a coherent picture of 
cancer and treatment-related cognitive change over time. Based on our results 
from such analyses as presented in Chapters III-IV (Nudelman et al. (2014); 
Nudelman et al. (under review)), we suggest that future studies including 
functional and metabolic data (fMRI and PET) would contribute significantly to 
this area of research, as identifying the number and type of independent versus 
correlated imaging results would significantly aid in our attempt to quantify the 
number and type of contributing biological mechanisms. Additionally, based on 
results presented in Chapter IV (Nudelman et al. (under review)), it will be very 
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important for future studies to consider other types of cancer and treatment-
related sequelae in relation to cognitive dysfunction.  
We suggest two research programs which might address some of the 
questions raised in the study presented in Chapter IV (Nudelman et al. (under 
review)). The first study would collect a sample (N>50) of breast cancer patients 
treated with and without chemotherapy and measure self-reported CIPN 
symptoms (using the FACT/GOG-Ntx), clinical grade of CIPN, and self-reported 
cognitive dysfunction (using the Multiple Ability Self-Report Questionnaire 
(MASQ)). This study would enable us to establish the relationship between the 
clinical level of CIPN and cognitive complaints. The second study would allow a 
comprehensive, integrated examination of objective and subjective forms of 
CIPN and cognitive complaints following cancer chemotherapy. This study would 
include self-reported CIPN symptoms (using the FACT/GOG-Ntx), clinical grade 
of CIPN, self-reported cognitive dysfunction (using the Multiple Ability Self-Report 
Questionnaire), neuroimaging (MRI-based perfusion and gray matter density 
measures), and an objective measure of peripheral neuropathy such as a skin 
biopsy or neurophysiological measurement. This study, while much more 
expensive than the first, would permit analysis of association between all 
measures, as well as investigation of the impact of the positive association 
between CIPN symptoms/perfusion and gray matter density on perceived versus 
actual CIPN. These findings would be able to demonstrate whether lower frontal 
gray matter density in chemotherapy-treated breast cancer patients was 
associated with a difference in perceived compared to actual (objective) CIPN, 
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which could have important clinical implications, as treatment needs for CIPN are 
typically assessed via patient self-report.  
Another future direction involves our observation of lower gray matter density 
in cancer survivors in the ADNI cohort, which highlights the importance of further 
investigation of the impact of cancer and treatment on aging and 
neurodegenerative processes. One recommendation to pursue this objective is to 
obtain cohorts of older cancer survivors, as most studies of cancer and 
treatment-related cognitive dysfunction are currently conducted on participants 
less than 65 years old [34]. Another recommendation is to study cohorts of 
individuals for longer periods of time after treatment; to date, longitudinal studies 
have only followed survivors for less than two years, though cross-sectional 
studies have identified cognitive dysfunction in survivors more than 20 years 
post-treatment [12,14-17,58,64,139]. Finally, it is vital that future studies continue 
to collect larger cohorts to permit genetic analysis, which will advance 
understanding of risk factors for cancer and treatment-related cognitive 
dysfunction. A future direction of the ADNI cohort analysis includes performing 
genome-wide association analysis of the frontal region of lower gray matter 
density in cancer survivors as an endophenotype of cancer/treatment-related 
cognitive dysfunction. However, the ADNI dataset, while much larger than those 
typically acquired in cancer neuroimaging studies, is still limited in sample size 
for this type of analysis; future research must therefore focus on identifying 
additional sample sets with appropriate data to continue these analyses, as well 
as collecting additional large genetic studies to enable progress in this area. 
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Identification of the driving biological mechanisms behind this effect may also 
provide direction towards the study of the inverse effect of cancer and AD, and 
the impact of cancer survivorship on the neurodegenerative process, highlighting 
the importance of this research program. Given the current lack of effective 
treatments for AD, this knowledge could have a vital impact on future therapeutic 
research.  
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